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Human embryonic stem cell (hESC) has great potential in tissue engineering 
and regenerative medicine due to its unlimited proliferation capacity and 
versatile ability to differentiate into almost all other cell types. One of the key 
features of hESCs is that they exhibit high telomerase activity to maintain their 
long and stable telomeres. However, once hESCs differentiate into other 
somatic cell types, their telomerase activity either decreases significantly or 
becomes completely absent, resulting in shortening of telomere length. 
Without telomerase activity, hESC-derived cells are susceptible to replicative 
telomere erosion, chromosome instability and cellular senescence due to the 
shortened telomere. Since the loss of telomerase activity during differentiation 
and shortening of telomere in later expansion are an inevitable outcome for 
hESC progenies, knowledge of how hESC derived cells age as well as method 
to generate hESC derived cells which are more resistant to ageing are 
important in hESC-related tissue engineering and regenerative medicine 
studies. In this study, we focused on telomerase and telomere maintenance in 
hESCs, to look into the ageing properties of hESC derived cells and explored 
possible ways to generate hESCs or hESC derived cells which could better 










The aims of the study were: 
1. To determine changes in telomere and telomerase during the course of 
differentiation from hESCs to somatic cell types (fibroblasts, keratinocytes, 
endothelial cells and neurons). 
2. To establish culture conditions to generate hESCs with longer telomere 
length.  
3. To define the cellular mechanisms of how hESCs maintain their telomere 
and telomerase. 
Hypotheses 
The main hypothesis in this study is that: hESCs can be optimized through 
routine maintenance to have longer telomere so that this feature can passed on 
to progeny cells derived from them to make these cells more durable in in 
vitro expansion and less susceptible to cellular senescence. To support this 
hypothesis, (i) the change of telomerase and telomere during differentiation 
from hESCs to progeny cell types should be observed; (ii) shortening of 
telomere and loss of telomerase activity in hESC-derived cells during 
differentiation and expansion should be observed; (iii) hESCs can be 
optimized to be longer through external stimulation during maintenance and 
(iv) the hESC progenies should be able to inherit the different telomere length 







To verify the above hypotheses, four stages of experiments were carried out as 
follows: 
Stage 1. Telomere length, hTERT expression and telomerase activity were 
assessed on H1 and H9 hESCs of different passages (range from Passage 47 to 
Passage 160 since the first culture in our lab). Same assessments were also 
conducted on hESC differentiated cells – fibroblasts, neurons, keratinocytes 
and endothelial cells from different source of hESCs.  
Stage 2. The culture systems of hESCs with different telomere length were 
compared; components that are different in these culture systems were 
identified and assessed. The culture systems were manipulated by swopping or 
conditioned with exogenous basic fibroblast growth factor (bFGF) to 
determine the key determinant that affect the telomere length of hESCs. 
Stage 3. The mechanism of how telomere length is controlled in hESC was 
explored by investigating bFGF stimulation and Wnt signaling pathway. 
Stage 4. Genetically identical H1 ESCs of long telomere and short telomere 
were differentiated to Embryoid body fibroblasts (ebFs) ebFs at the same time 
using same protocol. The telomere length of ebFs derived from these two 
populations of H1 hESCs was monitored and compared during the course of 
differentiation. 
Results 
In this study, we demonstrated that during differentiation and later expansion 
of hESC-derived cells (fibroblasts, endothelial cells, keratinocytes and 






shortening of telomere. We also found there was significant difference in 
telomere length of hESC in different culture systems where hESCs cultured in 
mTeSR™1 system have significantly longer telomere compared to those 
cultured in MEF feeder system. Further analysis on different culture systems 
revealed that bFGF might play an important role in regulation of hTERT and 
telomere in hESCs. We later demonstrated that bFGF influence hTERT 
probably through crosstalk of FGF signaling pathway and Wnt/β-catenin 
signaling pathway. Finally, we showed that the length of hESC telomere can 
be inherited by its progeny cells. 
Conclusions 
Basic FGF (bFGF) is not only essential for pluripotency and self-renewal of 
hESCs, but also plays an important role in maintaining hESCs’ telomere 
length. By increasing the concentration of bFGF, telomere could be 
lengthened in hESCs. The difference of telomere length does not affect the 
pluripotency and self-renewal of hESCs, but it might be important for cells 
that derived from them. A longer telomere in telomerase-negative hESC 
progenies might be an advantage for these cells to cope with replicative 
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Human embryonic stem cell (hESC) has great potential in regenerative 
medicine due to its unlimited proliferation capacity and versatile ability to 
differentiate into almost all other cell types. One of the key features of hESCs 
is that they exhibit high telomerase activity to maintain their extremely long 
and stable telomeres. However, once hESCs differentiate into other somatic 
cell types, their telomerase activity either decreased significantly or become 
completely absent, resulting in shortening of telomere length. Ageing-like 
features such as decreasing proliferation and senescence start to emerge 
(Armstrong et al., 2005). As such, knowledge of how hESC derived cells age 
as well as method to generate hESC derived cells which are more the resistant 
to ageing are important in hESC-related regenerative medicine studies, 
because these information will likely impact how the cells are prepared prior 
to application as well as their survival and functionality after implantation. In 
this study, we investigated telomerase and telomere maintenance in hESCs, to 
look into the ageing properties of hESC derived cells and explore novel 
approaches to generate hESCs or hESC derived cells which could better cope 
with replicative telomere erosion and cellular senescence.  
1.1 Telomere and telomerase 
1.1.1 Telomere 
Telomeres are repetitive DNA structures at the end of linear chromosomes, 
which usually consists of a double strand region of 10 – 20 kb of tandem 






strand region of a few hundred nucleotides at the 3′ end of the telomere 
(Blackburn, 1991).  
1.1.1.1 Capping for chromosomes 
Genomic stability and integrity must be maintained for an organism to 
function and propagate successfully and telomeres are one of several key 
elements required for genomic stability (McEachern et al., 2000). This was 
studied by McClintock and Muller, who found similar results in maize and 
fruitfly Drosophila melanogaster that chromosomes ends always fused with 
each other, but not for telomeres. Hence, telomeres were hypothesized to 
function to prevent chromosome fusion. It was also shown by McClintock that 
when a broken chromosome without telomere is replicated, the chromosome 
ends could possibly fuse and result in new break due to mechanical rupture 
during anaphase (McClintock & McClintock, 1938). The consequences of fuse 
and break cycle are severe because these breaks can lead to irregular 
segregation of genetic material into two daughter cells (McClintock, 1942). 
More recent work also showed that telomeres never fuse to a double-stranded 
break in DNA thus they are protected from end-joining reactions which 
usually repairs broken DNA (Muller & Herskowitz, 1954). The specialized 
DNA-protein complex distinguishes a normal chromosome end from a double-
stranded DNA break. The “capping” function of telomeres also protects 
chromosome ends against uncontrolled nucleolytic activity and excessive 








1.1.1.2 The end-replication problem 
Linear DNA molecules such as eukaryotic nuclear chromosomes require 
special mechanisms on top of the conventional DNA polymerases to complete 
the replication of their very extreme termini. The normal replication apparatus 
of cells carries out semiconservative DNA replication, copying a parental 
DNA strand as originally proposed by Watson and Crick (Watson & Crick, 
1953).  
Because DNA replication does not begin at either end of the DNA strand, but 
starts in the center, and considering that all DNA polymerases that have been 
discovered move in the 5' to 3' direction, thus there is a leading strand which 
has a 5’ end is replicated towards the end of chromosome, and a lagging strand 
which has a 3’ end is replicated in the other direction. On the leading strand, 
DNA polymerase can make a complementary DNA strand without any 
difficulty because it goes from 5' to 3'. However, there is a problem in the 
other direction on the lagging strand. To counter this, short sequences of RNA 
acting as primers attach to the lagging strand a short distance ahead of where 
the initiation site was. The DNA polymerase can start replication at that point 
and go to the end of the initiation site. This causes the formation of Okazaki 
fragments (Okazaki et al., 1968). More RNA primers attach further on the 
DNA strand and DNA polymerase attaches and continues to synthesize a new 
DNA strand. 
Eventually, the last RNA primer attaches, and DNA polymerase, RNA 
nuclease and DNA ligase convert the RNA (of the primers) to DNA and to 






DNA, there must be another DNA strand in front of the RNA primer. This 
happens at all the sites of the lagging strand, except at the end where the last 
RNA primer is attached. RNA is degraded by enzymes that degrade any RNA 
left on the DNA. Thus, a section of the telomere is lost during each cycle of 
replication at the 5' end of the lagging strand, this is called the “end-replication” 
problem (Figure 1a) (Watson, 1972). Due to this problem, each daughter DNA 
would be shorter on the 5’ end strand after each replication (Levy et al., 1992). 
 
Figure 1a. The DNA end-replication problem. During the S phase of the cell 
cycle, the chromosomal DNA is copied by a replication fork moving from an 
interior position on the chromosome towards the end of the linear 
chromosomal DNA molecule. Leading strand synthesis can theoretically copy 
the bottom parental strand to its last nucleotide. Discontinuous lagging strand 
synthesis by polymerase–primase copies the top parental strand as shown, 
primed by RNA primers. The RNA primers are then removed, and the internal 
gaps are filled by extension of the discontinuous DNA and ligation. However, 
degradation of the most distal RNA primer leaves a 5’ terminal gap. Following 
subsequent rounds of DNA replication, if the semi-conservative DNA 
replication machinery operates, as shown here, accumulation of such gap will 
result in progressively shortening of daughter DNA (Illustration is modified 
from Chan & Blackburn, 2004). 
 
Bacteria generally escape this problem by having circular chromosomal DNAs. 
Many bacteriophage and viruses with linear genomes bypass this problem in 






DNA replication intermediate while others use a covalently attached terminal 
protein for DNA priming. Some viruses actually have the end of their linear 
DNA genome closed in a covalently closed loop, with replication proceeding 
all the way around the end of the loop, and then the two daughters separating 
by being cut apart (Blackburn, 1984). In contrast, eukaryotic nuclear 
chromosomes use a very different mechanism to solve the problem of 
completing the replication of their ends. This process involves telomerase. 
1.1.2 Telomerase 
1.1.2.1 Discovery of telomerase 
Telomerase is the solution to the end-replication problem. Telomeric DNA 
consists of simple, G-rich tandem repeats, which is determined by the action 
of telomerase. Telomerase adds telomere repeats to the 3′ end of DNA strands.  
Telomerase was originally discovered by directed biochemical assays in vitro, 
using cell extracts and substrates designed to mimic telomeric DNA termini 
(Greider & Blackburn, 1985). This polymerization action was then shown to 
occur on natural telomeres in vivo (Yu et al., 1990). Initially called ‘telomere 
terminal transferase’, the enzyme was subsequently dubbed ‘telomerase’ 
(Greider & Blackburn, 1987), by which name it has been known since then. 
Discovery of this polymerization action of telomerase established the role of 
telomerase as a polymerase that extends one telomeric DNA strand. Synthesis 
of the complementary strand of the telomeric repeats is presumed to occur 







The synthesized telomeric DNA repeats attract and bind to a set of DNA 
sequence-specific binding proteins. These proteins in turn bind a further set of 
other proteins to form higher order complex nucleated on the telomeric DNA. 
Addition of telomeric DNA onto chromosome ends by telomerase serves to 
balance the losses predicted from the end-replication problem and from 
nuclease action (Wellinger et al., 1996), or potentially other DNA damage 
(Zglinicki et al., 2001) at telomeric DNA ends.  
1.1.2.2 Components of telomerase 
Telomerase is a specialized cellular reverse transcriptase (RT) which  consists 
of a catalytic subunit of reverse transcriptase called TERT (hTERT in human), 
an RNA template called TERC (hTERC in human) (Morin, 1989; Nugent & 
Lundblad, 1998). In the process of telomere elongation, chromosome terminus 
works as primer for TERT, which is positioned in an alignment site in TERC. 
Each process results in one additional telomeric repeats to the 3’ end and 
repeated processes give rise to identical new telomeres (Figure 1b) (Greider & 
Blackburn, 1985).  
 
Figure 1b. Telomerase add six-nucleotide repeating sequence to chromosome 
end. Telomerase binds to 3’ flanking end of telomere which is complementary 
to partial of telomerase RNA (3’CAAU5’). Bases are added using RNA as 
template. Then, telomerase shift to the next position and the elongation 
repeated. DNA polymerase complements the lagging strand from 5’ to 3’ (the 







The expression of TERC is high in all tissues, regardless of telomerase activity 
(Avilion et al., 1996). In contrast, the expression of TERT is much lower in 
tissues and closely related to telomerase activity (Yi et al., 1999). Moreover, 
over expression of TERT can significantly increase the telomerase activity and 
telomere length; however, over expression of TERC alone does not result in 
telomerase activity increasing or telomere lengthening (Cristofari & Lingner, 
2006). All these information suggested that TERT is the primary factor for the 
enzyme activity. 
1.1.3 The shortening of telomere and senescence in cells  
Telomerase activity was found to be absent in most normal human somatic 
cells but present in stem cells and over 90% of cancerous cells and in vitro-
immortalized cells (Shay & Bacchetti, 1997; Kim et al., 1994). 
In telomerase inactive cells, gradual telomere shortening eventually leads to 
loss of chromosome end protection. The link between telomere shortening and 
cellular senescence is seen most directly by decreasing function of genes that 
either encode telomerase components or control telomerase action in the cell 
where progressive telomere shortening is accompanied by a declining rate of 
proliferation of the cell population (Blackburn, 2000). Various normal somatic 
cells from humans, mice or chickens, which lack telomerase activity, exhibit 
progressive overall telomere shortening when grown in primary culture and 
eventual senescence. Telomere shortening was also correlated with 
proliferation halt of human cells whose lifespan in culture had been 
temporarily extended with viral oncogenes (Counter et al., 1992). Consistent 






shortening was observed with prolonged cell culture in vitro as well as 
increased age in vivo (Lindsey et al., 1991; Hastie et al., 1990; Harley et al., 
1990; de Lange et al., 1990). Normal mammalian somatic cells in vitro divide 
a limited number of times, and the maximum number is called the Hayflick 
limit (Hayflick, 1965). At Hayflick limit, the telomere length is critically short 
and a permanent growth arrest or replicative senescence is triggered (Wright et 
al., 1989; Olovnikov, 1971; Counter et al., 1992; Hande et al., 1999; Blasco et 
al., 1997; Allsopp et al., 1992). 
The decrease of telomere length with ageing also occurs to adult stem cell 
populations which express telomerase but the telomerase activity is not 
sufficient to maintain their telomere length (Lindsey et al., 1991).  
Based on these observations, it was proposed that telomere shortening in these 
cell types is the property that limits cellular proliferation.  
1.1.4 Active telomerase allows cells with short telomeres to proliferate 
Genetically well-controlled experiments in both yeasts and human cells in 
culture clearly showed that bulk telomere length can be uncoupled from 
telomere functionality. In S. cerevisiae cells containing only a catalytically 
inactive mutant telomerase ribonucleoprotein (RNP), the entire cell population 
ceased to divide after a period of telomeric shortening. However, in 
genetically identical cells which contain various mutations in telomerases but 
still enzymatically active, the telomere were significantly longer. Similar 
findings were obtained, with a different set of telomerase mutants in budding 
yeast (Ware et al., 2000). These results showed that very short telomeres that 






presence of active telomerase. Similar results were also obtained by ectopic 
expression of the gene for hTERT in human cells. Such ectopic activation of 
telomerase in human fibroblast cells, which normally lack telomerase in 
culture, overcomes both senescence and crisis and allows the cells to become 
effectively immortalized (Bodnar et al., 1998; Zhu et al., 1999; Kim et al., 
2003). Ectopically expression of wild-type TERT results in simultaneous 
telomere lengthening (Bodnar et al., 1998). Because telomerase-mediated 
telomere lengthening was associated with restoring the proliferative capability 
of these cells, this appeared to reinforce the link between loss of telomere 
function and telomere shortness. Again the primary or viral oncogene-
transformed human cells were immortalized, with the cells continuing to 
proliferate and showing fewer chromosomal end-to-end fusions than the 
controls that received no hTERT (Zhu et al., 1999; Kim et al., 2003). Notably, 
however, the bulk telomeres in the long-term proliferating cells consistently 
became shorter, and remained shorter, than the telomeres in control cells that 
were entering crisis. 
In summary, all these results indicated enzymatically active telomerase could 
effectively rescue cells with short telomeres from entering proliferative halt. 
1.1.5 Telomere length and fate of cell 
Telomere length of human cells is readily measured experimentally, and thus 
has often been used as a criterion to try to deduce cellular proliferation history 
and future potential. For example, the short telomeres often seen in cancer 
cells were taken as evidence that the cells had gone through many rounds of 






progression of tumorigenesis (Hastie et al., 1990). In some studies, average 
telomere length in T cells has been used as an indicator of the number of times 
these T cells had divided (Hodes et al., 2002).  
A central theory of many studies had been that a fixed degree of average loss 
of telomeric DNA occurs each time a cell divides. In non-immortalized cells 
with no detectable telomerase in cell culture, so long as cell type, isogenicity 
and certain growth conditions are fixed, this assumption has an experimentally 
demonstrated basis. However, variable levels of oxidative stress correlate with 
increased telomere shortening rates (Zglinicki et al., 2001). Even more 
importantly, the theory becomes useless if telomerase is active, because 
telomerase action elongates telomeres.  
To summarize, the fate of cells can only be deduced from the length of 
telomere without the interference of telomerase activity and other conditions 
which could alter the telomere. 
1.1.6 Human embryonic stem cells (hESCs) maintain their telomere through 
telomerase 
Human ESCs firstly isolated hESCs from human blastocysts and successfully 
grew them in culture by Thomson and coworkers in 1998. Human ESCs are 
unique in that they can proliferate indefinitely in culture in an undifferentiated 
state as well as differentiate into any somatic cells. Human ESCs are reported 
to have long telomere and at the same time express high levels of telomerase 
activity to maintain it (Thomson et al., 1998). However, both telomerase 






become absent in somatic cells including stem cells in self-renewal tissues 
(Figure 1c) (Armstrong et al., 2005).  
 
Figure 1c. Telomere and telomerase dynamics in human stem cells. Germ cells 
have high levels of telomerase activity during rapid proliferation. Although 
telomerase activity is diminished in non-proliferating sperms and ova, it is 
highly activated after fertilization and maintained in ES cells and germ cells 
for the next generation. In the developmental stage, telomerase activity 
gradually decreases and diminishes in most somatic cells after birth. In adult 
stem cells, the level of telomerase activity is low or undetectable, and 
upregulated in committed progenitor cells which have high reproducible 
activity in each tissue but insufficient to stably maintain their telomere length. 
Thus, adult stem cells are considered to be mortal and finally senesce by 
telomere shortening. Cancer stem cells can be derived from normal stem cells, 
progenitor cells, or possibly somatic cells and might be immortal, having the 
capacity of indefinite self-renewal and proliferation (Illustration is modified 
from Hiyama & Hiyama, 2007). 
 
1.1.6.1 The length of telomere in hESCs 
Many groups mentioned their measurement of hESCs telomere length in their 
studies, although their studies did not actually focus on hESC telomere length. 






hESC is derived from is 12.22kb (Turner et al., 2010). Forsyth and coworkers 
mentioned in their studies that the telomere length of hESCs they used is 
12.5kb (H1) and 10.4kb (H9) (Forsyth & McWhir, 2008). A survey of 96 
hESCs cell lines was done by Zeng et al., they concluded that telomere length 
of these hESC is 12.02±1.01kb (Zeng et al., 2014). Amit and coworkers also 
found similar results that their H9 hESCs maintained their telomere between 
8kb and 12kb (Amit et al., 2000). Notably, all the above mentioned hESCs 
were all cultured in MEF feeder system.  
1.2 Culture systems of hESCs 
As hESC become a popular model not only in stem cell research, but also 
other relative research areas, a variety of studies were carried out to refine and 
optimize the protocols of hESC expansion and maintenance. Different culture 
media and coating materials were tested in labs all around the world, some 
were even commercialized. 
Among many published protocols for hESC culture, four protocols were 
recommended by WiCell® (http://www.wicell.org/home/support/stem-cell-
protocols/stem-cell-protocols.cmsx), namely: feeder-independent protocol 
using mTeSR™1 medium, feeder-independent protocols using E8 medium, 
feeder-dependent protocols using mouse embryonic fibroblast (MEF) and 
feeder-free protocols using MEF conditional medium. 
1.2.1 Maintenance of hESCs on MEF feeder 
The original protocol for hESC maintenance is modified from mouse 
embryonic stem cell (mESC) maintenance protocol, using same MEF feeders 






MEF are isolated from 12.5 to 13.5 days fetus (Robertson, E.J. 1987). They 
provide substrate support for the growth of hESCs through expression of 
adhesion molecules and production of extracellular matrix (ECM). They also 
produce growth factors, such as heparin sulfate proteoglycans and pigment 
epithelium derived factor into culture medium or to ECM so as to maintain the 
undifferentiated state of hESCs (Xie et al., 2004; Levenstein et al., 2008). 
Although the use of MEF as a feeder layer to support undifferentiated growth 
of hESCs is the most conventional method adopted worldwide, the molecular 
basis for is still not fully understood. The use of MEF also poses difficulties 
for future possible clinical applications of hESCs. For example, MEF have 
limited life span and normally reach senescence after 7 to 8 passages. The 
qualities of MEF from different batches vary significantly and thus require 
extensive testing before use. Moreover, the preparation of supportive MEF is 
time consuming and requires heavy labors. Using MEF also increases the risk 
of contaminating human cells with animal pathogens and viruses (Cobo et al., 
2005).  
1.2.2 Maintenance of hESCs in MEF conditional medium system 
The MEF feeders system roamed the hESC research till people decide to 
remove MEF feeders, because they caused possible contaminations when 
experiments were targeted to hESCs. And the isolation of hESCs was not 
usually 100% free of feeder cells. Three years later MEF conditional medium 
(CM) system emerged and freed hESC culture from possible contamination of 
MEF cells and freed researchers from heavy labor of preparing MEF cells in 
every passage of hESC (Xu et al., 2001). MEF CM system is essentially a 






the media used in MEF feeder system. 24-hour conditioning with inactive 
MEF feeder cells was needed before the medium can be used to support 
hESCs cultures. However, an additional 4ng/ml of bFGF is required to 
compensate the degradation of bFGF in the 24-hour conditioning (Lotz et al., 
2013). Furthermore, without the help of feeder layers, hESCs were attached to 
culture vessel using Matrigel™ coating instead. Compared to MEF feeder 
system, MEF CM system has the following advantages: firstly, it does not 
require repeated MEF seeding in each hESC passage, conditioned medium 
(CM) can be prepared in bulk and stored in frozen for up to 6 months to avoid  
batch-to-batch variation. Secondly, without the contamination of MEF feeder 
cells, hESCs were can be easily harvested for differentiation or analysis 
studies (Xu et al., 2001). 
1.2.3 Maintenance of hESCs in mTeSR™1 feeder free system 
The mTeSR™1 feeder-free culture system was first reported in 2006 (Ludwig 
et al., 2006), and later commercialized by STEMCELL technology. This 
system uses Matrigel™ as coating base for hESCs to attach and a cocktail of 
chemicals and growth factors are supplemented through culture medium. 
Compared to MEF feeder system, mTeSR™1 is defined and have limited 
batch-to-batch variation (Ludwig et al., 2006). mTeSR™1 feeder free system 
is one of the most widely-used feeder-free hESC culture system currently. 
1.2.4 Maintenance of hESCs in E8 feeder free system 
The E8 feeder free system is a defined animal-free and xeno-free hESC culture 
system based on optimized E8 medium (substitution of mTeSR™1 medium) 






medium removed all non-essential components including bovine serum 
albumin (BSA), 2-mercaptoethanol (BME) which are commonly used in 
previous published hESC medium; as well as TGFβ and LiCl which are 
included in previous product mTeSR™1 (Chen et al., 2011). E8 feeder free 
system is famous for its animal-free and xeno-free, however, it is also a 
relatively new hESC culture system which is not widely-used yet. 
1.3 Basic FGF and its function in hESC maintenance 
FGF signals, implicated in control proliferation, differentiation, migration, 
survival and polarity, are transduced through FGF receptors - FGFR1, FGFR2, 
FGFR3 and FGFR4. FGF receptors are consist of extracellular 
immunoglobulin-like (Ig-like) domains and cytoplasmic tyrosine kinase 
domain (Lee et al., 1989; Dionne et al., 1990; Partanen et al., 1990; Partanen 
et al., 1991; Powers et al., 2000; Katoh & Katoh, 2003). FGF receptor 
isoforms with distinct ligand affinity are generated due to alternative splicing 
of mutually exclusive exons for the latter half of the third Ig-like domain. FGF 
dimers associated with heparan sulfate proteoglycan bind to FGF receptors to 
induce receptor dimerization, tyrosine kinase activation, and receptor 
autophosphorylation (Eswarakumar et al., 2005; Dailey et al., 2005). FRS2 
(FRS2a), FRS3 (FRS2b) and PLCγ are recruited to the autophosphorylated 
FGF receptors through the interaction with phospho-tyrosine residues. 
Basic FGF (bFGF) induces biological responses by binding to and activating 
FGFR1, in combination with heparan sulphate to form FGF/FGFR/heparan 
dimer. The dimerization of the receptor results in the transphosphorylation of 






cytoplasmic signal transduction pathways, such as: 1. MAPK signaling 
pathway which is associated with proliferation and differentiation; 2. PLCγ 
signaling pathway which is responsible to cell morphology and migration, and 
3. PI3K/Akt signaling pathway which is associated with cell survival and 
epithelial-mesenchymal transition (Dailey et al., 2005; Mohammadi et al., 
2005; Schlessinger, 2000). (Figure 1d) 
 
Figure 1d. FGF signaling pathway. FGF signals are transduced to the 
PI3K/Akt and MAPK signaling cascades through FRS2 or FRS3 docking 
proteins, and also to DAG-PKC and IP3-Ca2+-release signaling cascades 
through PLCγ. PI3K/Akt signaling cascade is essential for FGF-induced 
epithelial-mesenchymal transition (EMT) and cell survival. FGF-dependent 
PI3K/Akt signaling activation leads to GSK3β inactivation which is dependent 
on phosphorylation at serine 9 residue. (Illustration is modified from Katoh & 
Katoh, 2006). 
Despite the different roles of FGF signals, the role of FGF signaling in hESCs 
is mainly maintaining the self-renewal and pluripotency (Amit et al., 2000; 
Levenstein et al., 2006; Xu et al., 2001). Using cDNA microarray analysis and 






undifferentiated hESCs express elevated level of bFGF and all four types of 
FGF receptors, with FGFR1 as the most abundant receptor followed by 
FGFR4, FGFR3 and FGFR2 in the descending order (Dvash et al., 2004; 
Dvorak et al., 2005; Ginis et al., 2004; Rao et al., 2004; Sperger et al., 2003; 
Wei et al., 2005). Together, hESCs have been demonstrated to be well 
equipped to accept and transmit both exogenous and endogenous FGF signals.  
As mentioned earlier, downstream of FGF signaling, both MAPK and PI3K 
are activated following bFGF stimulation. Studies found that activated PI3-K, 
rather than MAPK, can mediate pluripotent marker expression (Ding et al., 
2010). It was also reported that exogenous bFGF is required for the 
maintenance of pluripotency, but not the proliferation of hESCs (Eiselleova et 
al., 2009; Ding et al., 2010).  
In summary, bFGF plays a complex multilevel role in the maintenance of 
hESC pluripotency. Although intracranial bFGF signaling maintains 
pluripotency gene expression, the exogenous bFGF supplementation of hESC 
culture media primarily contributes to the maintenance of hESC pluripotency 
by promoting cell adhesion and survival (Eiselleova et al., 2009).  
1.4 Wnt signaling pathway  
Wnt signals are transduced to the canonical signaling pathway (also known as 
Wnt/β-catenin signaling pathway) for cell-fate determination, and to the non-
canonical signaling pathway for the control of tissue polarity and cell 







Figure 1e. Canonical & Non-canonical Wnt signaling pathways. Canonical 
Wnt signals are transduced to the β-catenin/TCF signaling cascade to 
determine cell fate. Non-canonical Wnt signals are transduced to the RHOA, 
c-Jun N-terminal kinase (JNK), and Nemo-like kinase (NLK) signaling 
cascades to control tissue polarity and cell movement. Wnt signals are context-
dependently transduced to the canonical pathway or the non-canonical 
pathway based on the expression profile of Frizzled family receptors, other 
coreceptors, and cytoplasmic signaling class switchers. Canonical Wnt 
signaling activation leads to GSK3β inactivation independent of Ser9 
phosphorylation (Illustration is modified from Katoh & Katoh, 2006).  
 
Frizzled-1 (FZD1), FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9 
and FZD10 are seven transmembrane-type Wnt receptors with cytoplasmic 
Dishevelled-binding motif, which are implicated in both canonical and non-
canonical Wnt signaling pathways (Wang et al., 1996; Bhanot et al., 1996; 
Sagara et al., 1998; Kirikoshi et al., 2000; Kirikoshi et al., 1999; Koike et al., 







1.4.1 Canonical Wnt signaling pathway (Wnt/β-catenin signaling pathway) 
Canonical Wnt signals are transduced through Frizzled family receptor and 
LRP5/LRP6 coreceptor (Pinson et al., 2000; Tolwinski et al., 2003; Schweizer 
& Varmus, 2003). LRP5 and LRP6 are LDL family proteins with extracellular 
Wnt-binding region and cytoplasmic AXIN-binding motif. Without canonical 
Wnt signaling, the β-catenin would not accumulate in the cytoplasm since β-
catenin is bonded with and phosphorylated by GSK3β for the ubiquitination 
and the following proteasome mediated degradation. This destruction complex 
includes the following proteins: Axin, adenomatosis polyposis coli (APC), 
protein phosphatase 2A (PP2A), glycogen synthase kinase 3 (GSK3) and 
casein kinase 1α (CK1α). It degrades β-catenin by targeting it for 
ubiquitination, which subsequently sends it to the proteasome to be degraded 
(MacDonald et al., 2009; Rao & Kühl, 2010). Canonical Wnt signals induce 
the assembly of Frizzled-Dishevelled complex and LRP5/6-AXIN-FRAT 
complex to release β-catenin from GSK3β for its stabilization and nuclear 
accumulation. Nuclear β-catenin is associated with TCF/LEF family 
transcription factors (TCF1, LEF1, TCF3 and TCF4) as well as Legless family 
docking proteins (BCL9 and BCL9L). TCF/LEF are HMG-box transcription 
factors binding to the promoter region of FGF18, bFGF0, DKK1, MYC, and 
CCND1 genes. (Shimokawa et al., 2003; Chamorro et al., 2005; Katoh & 
Katoh, 2005; He et al., 1998; Tetsu & McCormick, 1999). Legless family 
docking proteins link β-catenin to PYGO family coactivators (PYGO1 and 
PYGO2). The TCF/LEF-β-catenin-Legless-PYGO nuclear complex is the 







Figure 1f. On and off state of Canonical Wnt signaling pathway (Wnt/β-
catenin signaling pathway). Without Wnt signaling, the β-catenin would not 
accumulate in the cytoplasm since a destruction complex would normally 
degrade it. This destruction complex includes the following proteins: Axin, 
APC, PP2A, GSK3 and CK1α. It degrades β-catenin by targeting it for 
ubiquitination, which subsequently sends it to the proteasome to be digested. 
However, as soon as Wnt binds Fz and LRP-5/6, the destruction complex 
function becomes disrupted. This is due to Wnt causing the translocation of 
both a negative regulator of Axin and the destruction complex to the plasma 
membrane. This negative regulator becomes localized to the cytoplasmic tail 
of LRP-5/6. Phosphorylation by other proteins in the destruction complex 
subsequently binds Axin to this tail as well. Axin becomes de-phosphorylated 
and its stability and levels are decreased. Dsh then becomes activated via 
phosphorylation and its DIX and PDZ domains inhibit the GSK3 activity of 
the destruction complex. This allows β-catenin to accumulate and localize to 
the nucleus and subsequently induce a cellular response via gene transduction 
alongside the TCF/LEF transcription factors (Illustration is adopted from 








1.4.2 Non-canonical Wnt signaling pathway 
Non-canonical Wnt signals are transduced through Frizzled family receptor 
and ROR1/ROR2 coreceptor. ROR1 and ROR2 are receptor-type tyrosine 
kinases with extracellular Wnt-binding region and cytoplasmic casein kinase 
Ie (CKIe)-binding domain (Katoh & Katoh, 2005; Katoh & Katoh, 2005). 
RHOA, c-Jun N-terminal kinase (JNK), and Nemo-like kinase (NLK) are 
effector molecules of the non-canonical Wnt-signaling pathway, which was 
reviewed elsewhere (Katoh, 2005). Wnt1, Wnt2, Wnt2B, Wnt3, Wnt3A, Wnt6, 
Wnt8A, Wnt8B, Wnt10A, Wnt10B are classified as canonical Wnts, while 
Wnt5A, Wnt5B, Wnt11, etc., are classified as non-canonical Wnts (Katoh, 
2002). Together, these facts indicate that Wnt signals are context-dependently 
transduced to the canonical Wnt signaling pathway and the non-canonical Wnt 
signaling pathway based on the expression profile of FZD family receptors, 
other coreceptors, and cytoplasmic signaling class switchers (Figure 1e).  
1.4.3 The link between Wnt/β-catenin signaling pathway and telomerase 
Previous studies had shown close association of TERT expression (telomerase 
activity) and Wnt/β-catenin (canonical Wnt) signaling pathway; however, 
which one is the causation of the other is still under debate. 
The Wnt/β-catenin signaling pathway has previously been shown to activate 
telomerase (Broccoli et al., 1996), and mutations in APC (Park et al., 2009) 
and GSK3 (Bilsland et al., 2009), important regulators of the Wnt pathway, 
also increase telomerase activity. There have also been studies have proposed 
that the Wnt pathway is linked to TERT in a quite different way. Constitutive 






TERT may also function as a transcription factor (Park et al., 2009). Although 
one study did not observe Wnt pathway activation in response to TERT 
overexpression (Mukherjee et al., 2011), other studies have raised questions 
about the physiological relevance of the constitutive over-expression of TERT. 
Deletion of TERT in mice does not affect expression of target genes in the 
Wnt pathway (Vidal-Cardenas & Greider, 2010), nor give rise to the cellular 
phenotypes that loss of Wnt signaling induces (Strong et al., 2011), indicating 
that TERT regulation of Wnt signaling may be limited to situations where 
TERT is over-expressed. 
However, recent study by Hoffmeyer et al. gave an insight of the real 
connection of Wnt/β-catenin signaling pathway and TERT expression. They 
analyzed the pathway through which Wnt signaling activates the enzyme and 
found that TERT transcription is substantially reduced in β-catenin–deficient 
mouse embryonic stem cells and in adult stem cells. By expressing a 
constitutively stable form of β-catenin, it was shown that in vivo, β-catenin 
expression increases TERT transcription. The effect is direct because β-
catenin binds to the TERT promoter, as shown by reporter assays and 
chromatin immunoprecipitation (Hoffmeyer et al., 2012). This is in contrast to 
indirect activation of TERT transcription by β-catenin, in which the 
transcription factor c-Myc directly controls TERT transcription through c-Myc 
(Wang et al., 1998), which itself is transcriptionally regulated by β-catenin. 
Furthermore, the authors show that the protein Klf4, rather than the usual 
suspect for a β-catenin DNA binding partner, TCF1-4, cooperates with β-
catenin to induce TERT expression. This puts a new twist on regulation by the 






Furthermore, it was reported that in hESCs, modulating Wnt/β-catenin signal 
pathway but not the other Wnt signal pathway, promotes hESC renewal (Cai 
et al., 2007). It was also reported that endogenous Wnt/β-catenin signal is 
required by hESC to maintain an undifferentiated state (Melchior et al., 2008). 
In summary, it is reasonable to propose that Wnt regulates TERT given that 
Wnt signaling plays an essential role in stem cell self-renewal and that TERT 
is needed for the long-term growth of stem cells. TERT regulation seems to 
require not one, but two master transcriptional regulators. The finding by 
Hoffmeyer et al. that both β-catenin and Klf4 are required to activate TERT 
expression confirms that Wnt signaling regulates TERT and provides a 
foundation for linking telomerase levels and self-renewal. 
1.5 Crosstalk of bFGF pathway and Wnt signaling pathway 
Wnt and FGF signaling pathways cross-talk during a variety of cellular 
processes, such as human colorectal carcinogenesis, mouse mammary tumor 
virus (MMTV)-induced carcinogenesis (Shackleford et al., 1993; de La Coste 
et al., 1998; Satoh et al., 2000; Fearon & Vogelstein, 1990), E2A-Pbx-induced 
leukemogenesis (McWhirter et al., 1997; McWhirter et al., 1999), early 
embryogenesis (Loebel et al., 2003), body-axis formation (McGrew et al., 
1997), limb-bud formation (Tickle, 1995; Ng et al., 2002), and neurogenesis 
(Villanueva et al., 2002; Gunhaga et al., 2003).  
Wnt signals are transduced to the canonical signaling pathway and the non 
canonical-signaling pathway. FGF signals are transduced to the PI3K/Akt 
signaling pathway, the MAPK signaling pathway, and the PLCγ signaling 






Wnt signaling pathway, GSK3β is found to be the key component found in 
canonical Wnt signaling pathway as well as the FGF-dependent PI3K/Akt 
signaling pathway. 
1.5.1 Crosstalk of Wnt and FGF during carcinogenesis 
Crosstalk of Wnt and FGF were found in carcinogenesis in many studies. 
MMTV integrations around Wnt1, Wnt3, Wnt10b, Fgf3, Fgf4, Fgf8, Notch4, 
Cyp19a1 and Eif3s6 genes to induce mammary carcinogenesis through 
transcriptional activation of these genes (Lee et al., 1995; MacArthur et al., 
1995; Katoh, 2002). Mammary carcinogenesis in MMTV-Wnt1 transgenic 
mice is accelerated by MMTV infection due to MMTV integration around 
Fgf3-Fgf4 or Fgf8 loci, and mammary carcinogenesis in MMTV-Fgf3 
transgenic mice due to MMTV integration around Wnt1-Wnt10b locus. Wnt 
and FGF signaling pathways network together during MMTV-induced 
mammary carcinogenesis.  
Transcriptional activation of canonical Wnts during tissue regeneration 
induced by chronic persistent inflammation also lead to activation of the 
canonical Wnt signaling pathway (Figure 1g). Because FGF18 and FGF20 are 
target genes of the canonical Wnt signaling pathway, activation of the 
canonical Wnt signaling pathway during carcinogenesis leads to FGF 







Figure 1g. Crosstalk of Wnt and FGF signaling pathways during 
carcinogenesis. GSK3β downregulation induced by the canonical Wnt 
signaling pathway and by the FGF-dependent PI3K/Akt signaling pathway is 
independent of and dependent on Ser9 phosphorylation, respectively. 
Simultaneous activation of Wnt and FGF signaling pathways leads to the 
potentiation of the canonical Wnt signaling pathway through the promotion of 
the nuclear translocation of β-catenin by the FGF dependent PI3K/Akt 
signaling pathway (Illustration is modified from Katoh & Katoh, 2006). 
 
GSK3β downregulation induced by the canonical Wnt signaling pathway and 
by the FGF-dependent PI3K/Akt signaling pathway is independent of and 
dependent on Ser9 phosphorylation, respectively (Frame & Cohen, 2001). 
Simultaneous activation of Wnt and FGF signaling pathways leads to the 
potentiation of the canonical Wnt signaling pathway through the promotion of 
the nuclear translocation of β-catenin by the FGF dependent PI3K/Akt 
signaling pathway.  
GSK3β downregulation by the FGF-dependent PI3K/Akt signaling pathway 






the direct link between the canonical Wnt signaling pathway and the SNAIL-
EMT signaling cascade remains unclear, GSK3β downregulation by the 
canonical Wnt signaling pathway indirectly leads to the activation of SNAIL-
EMT signaling cascade through the transcriptional activation of FGF family 
members.  
Together, these facts indicate that Wnt and FGF signals activate both the β-
catenin signaling cascade and the SNAIL-EMT signaling cascade (Figure 1g). 
Therefore, co-activation of Wnt and FGF signaling pathways during 
carcinogenesis leads to more malignant phenotypes due to the potentiation of 
β-catenin and SNAIL-EMT signaling cascades.  
1.5.2 Crosstalk of FGF and Wnt signaling in hESCs 
From the above information of FGF signaling and Wnt/β-catenin signaling, it 
is found that both signaling pathway play important roles in pluripotency 
maintenance of hESCs. In hESCs, activation of both signaling pathway 
eventually result in expression of genes that maintain pluripotency and self-
renewal; however, both signaling pathways are also responsible for hESC 
differentiation (Welham et al., 2011). Thus, interactions between these two 
signaling pathway in hESCs is complicated. 
Studies showed that FGF signaling that activates PI3K/Akt maintains self-
renewal by restraining pro-differentiation signaling through suppression of the 
Raf/Mek/Erk and canonical Wnt signaling pathways. When active, PI3K/Akt 
establishes conditions where Activin A/Smad2,3 performs a pro-self-renewal 
function by activating target genes, including Nanog. When PI3K/Akt 






Smad2,3 to promote differentiation. The switch in Smad2,3 activity after 
inactivation of PI3K/Akt requires the activation of canonical Wnt signaling by 
Erk, which targets GSK3β (Eiselleova et al., 2009). 
Interestingly, another study focused on undifferentiated hESC reported that 
when PI3K signaling pathway was simulated by bFGF, GSK3β is inhibited 
and followed by nuclear translocation of β-catenin and TCF/LEF. This showed 
that bFGF signaling actually activates Wnt/β-catenin signaling pathway 
instead of suppressing it (Figure 1h) (Ding et al., 2010). 
To summarize, it can be deduced that whether FGF signaling pathway 
modulate Wnt/β-catenin signaling pathway positively or negatively depends 
on whether hESCs are in undifferentiated state. When hESCs are in 
undifferentiated state, stimulation of bFGF promotes the pluripotency genes as 
well as Wnt/β-catenin signaling pathway which further enhance the 







Figure 1h. Crosstalk of Wnt and FGF signaling pathways in undifferentiated 
hESCs. Upon bFGF stimulation, GSK3β is phosphorylated following which 
nuclear translocation of β-catenin and TCF/LEF activation occurs (Ding et al., 
2010). Signals from both pathways in turn promote the expression of 
pluripotency and self-renewal markers e.g. Oct4, Sox2 & Nanog (Boiani & 






















Hypotheses and Objectives 
Hypothesis 
The main hypothesis in this study is that: hESCs can be optimized through 
routine maintenance to have longer telomere so that these features can passed 
on to progeny cells derived from them to make these cells more durable in in 
vitro expansion and less susceptible to cellular senescence. To support this 
hypothesis, (i) the change of telomerase and telomere during differentiation 
from hESCs to progeny cell types should be observed; (ii) shortening of 
telomere and loss of telomerase activity in hESC-derived cells during 
differentiation and expansion should be observed; (iii) telomere of hESCs can 
be optimized to be longer through external stimulation during maintenance 
and (iv) the hESC progenies should be able to inherit the different telomere 
length from their respective hESCs. 
Objectives 
The aims of the study were: 
1. To determine changes in telomere and telomerase during the course of 
differentiation from hESCs to somatic cell types (fibroblasts, keratinocytes, 
endothelial cells and neurons). 
2. To establish culture conditions to generate hESCs with longer telomere 
length.  
3. To define the cellular mechanisms of how hESCs maintain their telomere 
and telomerase. 
4. To determine if difference of telomere length in hESCs can be inherited by 
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To verify the above hypotheses, four stages of experiments were carried out as 
follows: 
Stage 1. Telomere length, hTERT expression and telomerase activity were 
assessed on H1 and H9 hESCs of different passages (range from Passage 47 to 
Passage 160 since the first culture in our lab). Same assessments were also 
conducted on hESC differentiated cells – fibroblasts, neurons, keratinocytes 
and endothelial cells from different source of hESCs.  
Stage 2. The culture systems of hESCs with different telomere length were 
compared; components that are different in these culture systems were 
identified and assessed. The culture systems were manipulated by swopping or 
conditioned with exogenous basic fibroblast growth factor (bFGF) to 
determine if the changes could affect the telomere length of hESCs. 
Stage 3. The mechanism of how telomere length is controlled in hESC was 
explored by investigating bFGF stimulation and Wnt signaling pathway. 
Stage 4. Genetically identical H1 ESCs of long telomere and short telomere 
were differentiated to embryoid body fibroblasts (ebFs) ebFs at the same time 
using same protocol. The telomere length of ebFs derived from these two 


























Materials and Methods 
3.1 Mouse embryonic fibroblasts expansion and inactivation 
3.1.1 Mouse embryonic fibroblasts (MEF) expansion 
MEF culture medium comprised of 90% of DMEM high glucose medium and 
10% FBS. MEF were expanded in MEF culture medium for 3-4 passages, with 
a splitting ratio of 1: 5. Upon reaching 90% confluence, the cells were 
trypsinized with 0.05% Trysin EDTA (TE) (Life Technologies) at 37°C for 5 
minutes. The same MEF culture media was used to neutralize the TE and the 
cells centrifuged at 300× g for 3 minutes. The cells pellets were re-suspended 
in fresh MEF culture medium and seeded into a new culture flask for 
expansion.  
3.1.2 MEF inactivation 
MEF at passage 3 or 4 were inactivated with 10μg/ml mitomycin C (MMC) 
(Kyowa, USA). The MMC powder was initially dissolved in Hank’s balanced 
salt solution (SIGMA) to make a stock solution of 0.5mg/ml. The MMC stock 
solution was then added directly into the culture medium to a final 
concentration of 10μg/ml. After 2 hours of incubation in a 37 oC incubator 
supplied with 5% CO2 and 95% humidity, the MMC solution were removed 
and the culture vessels were washed three times with 1× PBS. The cells were 
then trypsinized by TE at 37°C as described above. The MEF were re-
suspended in MEF freezing medium (10% DMSO, 20% FBS & 70% DMEM 
high glucose) and frozen at 1.4 × 106 cells per ml per vial. The vials were pre-
freezed in -80oC freezer overnight in isopropyl alcohol (IPA) freezing 
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3.2 Human embryonic stem cell culture 
Human embryonic stem cells (hESC) H1 & H9 were used in this study. Both 
cell lines are NIH-registered and provided by WiCell Research Institute with 
agreement No.04-W094. 
Three different hESC culture systems were used in this study: MEF feeder-
dependent system, MEF conditioned medium system and mTeSR™1 feeder 
system. All three protocols mentioned here are recognized and listed on the 
WiCell official website (http://www.wicell.org/home/support/stem-cell-
protocols/stem-cell-protocols.cmsx).  
3.2.1 MEF feeder-dependent system (MEF system) 
The hESC culture medium for MEF feeder-dependent system (MEF system) 
was comprised of DMEM/F12 (Life Technologies) as basal medium, 
supplemented with 20% knockout serum replacement (Life Technologies), 
4ng/ml basic fibroblast growth factor (bFGF) (Life Technologies), 1mM 2-
Mercaptoethanol (BME) (SIGMA), 1% NEAA (SIGMA) and 1mM L-
glutamine (SIGMA). 
One day prior to seeding of hESC, freshly thawed inactivated MEF were 
plated on 1% gelatin coated 6 well plates at the density of 2.4×104 cells/cm2. 
On the day of hESC seeding, MEF medium was removed and culture wells 
were washed three times with 1×PBS after which 2ml of fresh hESC culture 
medium was added. 
When hESC reached approximately 70-80% confluence, they were treated 
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followed by manual picking under a dissecting microscope. Picked colonies 
were allowed to settle down in a 15-ml falcon tubes for about 1 minute, 
supernatant was then removed. The colonies were then re-suspended in fresh 
hESC medium and seeded on prepared inactivated feeder layers at about 1:6 
splitting ratio. The hESCs can be cultured in an incubator supplied with 37 oC 
temperature, 5% CO2 and 95% humidity for around 5-7 days with daily 
change of hESC media before the next passage. 
3.2.2 MEF conditioned medium system (MEF CM system) 
Fresh hESC culture medium (same in above mentioned MEF feeder-
dependent system) was used as un-conditioned medium. Inactivated MEF 
were seeded on 0.1% gelatin coated plate at the density of 5.6×104 cells/cm2. 
The cells were allowed to attach overnight in an incubator at 37oC temperature, 
5% CO2 and 95% humidity. The MEF medium was then replaced and washed 
three times with 1× PBS. Un-conditioned medium was then added at 
0.25ml/cm2 depending on the size of culture vessel. After 24 hours of 
conditioning in a 37oC temperature, 5% CO2 and 95% humidity incubator, the 
conditioned medium was harvested and additional 4ng/ml bFGF was added. 
The conditioned medium can either be used immediately or stored in -80oC for 
up to 1 year or 4oC for up to 14 days. 
One day before the passaging of hESC, Matrigel™ was coated on the culture 
surface. Ice-cold (4oC) Matrigel™ was dissolved in ice-cold DMEM/F12 
blank medium according to manufacturer’s instructions. The plates were 
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When hESC reached 70-80% confluence, they were treated with a mixture of 
1U/ml Dispase (STEMCELL Technologies) and the original remaining culture 
medium at a ratio of 1:1. In the meantime, Matrigel™ solution was removed 
from the plate prepared in previous day, and conditioned medium was added 
at 0.2ml/cm2 depending on the size of the culture vessel. After about 3 minutes 
incubation, Dispase was then removed and the plate was washed twice with 
DMEM/F12 blank medium. DMEM/F12 (0.1ml/cm2) was left in the culture 
well from which colonies were picked under a dissecting microscope and 
transferred to a 15-ml falcon tube. The picked colonies were pipetted up and 
down briefly and transferred to Matrigel™ coated plate with MEF conditioned 
medium. The passage ratio was about 1:6. The cells can be cultured for about 
5-7 days with daily change of MEF conditioned medium before the next 
passage. 
3.2.3 mTeSR™1 feeder free system (mTeSR™1 system) 
mTeSR™1 feeder free system is similar to the MEF CM system except that 
the conditioned medium is replaced with commercial mTeSR™1 medium 
(STEMCELL™ Technologies). A complete mTeSR™1 medium is a mixture 
of four portions of mTeSR™1 basal medium and one portion of mTeSR™1 
supplement. The completed mTeSR™1 medium can be either used 
immediately or stored at 4oC for up to 14 days. 
One day prior to passaging of hESC, Matrigel™ was coated on the culture 
surface. Ice-cold (4oC) Matrigel™ was dissolved in ice-cold DMEM/F12 
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incubated in a 37oC incubator supplied with 5% CO2 and 95% humidity for 
over night. 
When hESC reached 70-80% confluence, they were treated with a mixture of 
1U/ml Dispase (STEMCELL Technologies) and the original remaining culture 
medium at a ratio of 1:1. In the meantime, the Matrigel™ solution was 
removed from the plate prepared in previous day, and completed mTeSR™1 
media was added at 0.2 ml/cm2 depending on the size of culture vessel used. 
After about 3 minutes of incubation, Dispase was then removed and the plate 
was washed twice with DMEM/F12 blank medium. DMEM/F12 (0.1ml/cm2) 
was left in the culture well from which colonies were picked under a 
dissecting microscope and transferred to a 15-ml falcon tube. The picked 
colonies were pipetted up and down briefly and transferred to Matrigel™ 
coated plate with completed mTeSR™1 medium. The passage ratio was about 
1:6. The cells were cultured for around 5-7 days with daily change of 
completed mTeSR™1 medium before the next passage. 
3.3 Embryoid bodies (EBs) formation and embryoid body derived 
fibroblasts (ebF) differentiation of hESCs  
3.3.1 Conventional EB formation  
Human ESCs were differentiated to EBs as described previously. The hESC 
colonies were dissociated into small clumps through 5 minutes incubation with 
1 mg/ml collagenase type IV and then transferred to ultra-low attachment six-
well culture plates (Corning) in EB media consisting of 80% DMEM/F12 and 
20% knockout serum replacement supplemented with 1% (vol/vol) non-
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mercaptoethanol (BME). The suspended hESC clumps formed three-
dimensional (3D) free-floating aggregates or EBs. The EB medium was 
changed every 2 days.  
3.3.2 Spin-EB formation using forced aggregation using Aggrewell™  
Human ESC colonies were dissociated from the MEFs through a 30-40 
minutes incubation with 2 mg/ml collagenase type IV. The dissociated hESC 
clumps were dissociated into single cells through 10 minutes incubation with 
Accutase (StemCell Technologies). Pre-determined numbers of single hESC 
cells were seeded onto each well of Aggrewell™ 800 plates (StemCell 
Technologies) in Aggrewell™ media (STEMCELL Technologies) 
supplemented with 10μM Y27632 (Miltenyi Biotec). Single dissociated cells 
were forced to aggregate onto the microwells by centrifugation at 100 × g for 
5 minutes. The spin-EBs were harvested after 24 hours and transferred to ultra 
low-attachment six-well culture plates (Corning) in Aggrewell medium 
(StemCell Technologies). 
 3.3.3 Differentiation of hESCs to ebF  
H1 hESCs were differentiated to fibroblasts as described previously (Fu et al., 
2011). Briefly, Day 5 EBs were plated onto 1% gelatin coated tissue culture 
plates in fibroblast differentiation medium consisting of DMEM (high glucose) 
supplemented with 10% FBS (Life Technologies). The EB outgrowths were 
cultured and expanded for 5 passages upon attaining confluence. The EB 
outgrowths attained homogenous population of fibroblast-like cells from 3rd 
passage. These fibroblast-like cells would be termed as Passage 1 of H1-
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expanded either at ratio of 1:5 or at 5,000 cells/cm2 seeding density. TrypLE™ 
Express (Life Technologies) was used as dissociation reagent during 
passaging. 
3.4 Differentiation of keratinocyte from H1 ESCs 
H1 ESCs were differentiated into keratinocyte using protocol reported 
previously (Kidwai et al., 2013). H1 ebF feeder cells were obtained from H1 
hESCs as described previously (Section 3.3.3). H1 ebFs were inactivated in 
the same way as MEFs feeders (Section 3.1.2) and plated onto a gelatin-coated 
6-well plate at approximately 1.4×105 cells per well followed by H1 hESCs 
seeding on the next day. The H1 hESCs and H1 ebFs were co-cultured in ESC 
medium for 2–3 days before the start of differentiation. ESC medium was 
replaced by F12 and Dulbecco medium (mixture of 3:1 of DMEM and Ham’s 
F12 media supplemented with 50 mg/ml ascorbic acid (Sigma), 2% FBS, 5 
mg/ml insulin, 10 ng/ml recombinant human epidermal growth factor, and 
0.5mM of retinoic acid (RA)) for 25 days, with 25 ng/ml of Activin (catalog 
#338-AC, R&D Systems, MN) was introduced at day 9 for 3 days. After 25 
days, the differentiated cells were detached and seeded on human collagen 
type IVcoated flasks and kept in defined keratinocyte serum free medium 
(Life Technologies) without Activin and RA for expansion. 
3.5 Differentiation of endothelial cells from H1 ESCs 
The protocol of endothelial cells differentiation was published previously (Tan 
et al, 2013). H1 ESCs in mTeSR™1 system were used for endothelial cells 
differentiation. H1 ESC colonies were first dissociated into small clumps and 
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After 48h, mTeSR™1 medium was replaced with basal differentiation media 
(STEMdiff APEL; STEMCELL Technologies) supplemented with 5 mM 
GSKi (CHIR99021; Stemgent) for 5 days. To induce further differentiation 
toward the vascular endothelial, GSKi-treated hESCs were differentiated in 
the presence of 25ng/ml recombinant human bone morphogenetic protein 4 
(rhBMP4) for 24h and further treated with basal differentiation media 
supplemented with 50ng/ml vascular endothelial growth factor (VEGF) 
(Peprotech) and 25ng/ml rhBMP4 for 2 days. CD34+/KDR+ subpopulations 
were sorted using fluorescence-activated cell sorting (FACS; Dako 
Cytomation MoFlo cell sorter) and seeded onto collagen IV-coated plates. The 
post-sorted CD34+/KDR+ cells were further committed toward the endothelial 
lineage in ECGM-MV2 (Promocell) endothelial media supplemented with 
50ng/ml VEGF. 
3.6 Differentiation of neurons from H1 ESCs 
Prior to differentiation, H1 hESCs cultures were treated with 2mg/ml 
collagenase IV for 15-30 minutes to allow the colonies to detach from MEF 
feeders. The floating colonies were then collected into a 15ml tube for brief 
centrifugation. After removing the supernatant, the cell pellets were 
reconstituted in fresh hESCs media for 12 hours culture in tissue culture plates. 
The cell suspensions were then collected again leaving the contaminating 
MEF cells attached to the plates. The collected hESCs colonies would then be 
subjected to differentiation. To create single cell suspensions, the colonies 
were treated with Accutase (Stem Cell Technologies, Canada) for 5 minutes in 
a 37oC water bath. The cells were then neutralized with hESCs media and 
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re-suspended into respective media for differentiation. The culture vessels for 
differentiation were coated with thin layer of the fibronectin 1 hour prior to 
cell seeding at 4ng/cm2. Cells were induced to neural lineage cells with neural 
basal media supplemented with N2 supplement and Stem Pro neural 
supplement. The cells were then passaged on Matrigel™ coated plates and 
cultured for 7 days. Rosettes were then selected chemically followed by single 
cell dissociation. Cells were then cultured in neural basal media supplemented 
with 1× NEAA, 2mM L-Glutamine, 1× B27, 200ng/ml Shh and 50ng/ml 
FGF8 for 10 days followed by replacing Shh and FGF8 with 20ng/ml GDNF, 
1μM TGF-β3 and 1mM dcAMP for further expansion. 
3.7 Gene expression analysis by reverse transcription-polymerase chain 
reaction (RT-PCR) 
Cells for RT-PCR experiments were either removed from culture vessels by 
chemical dissociation or lysed directly in culture vessels. The dissociated cells 
or lysate were subjected to RNA extraction using MN NucleoSpin RNA kit 
(Macherey-Nagel, Germany), following the manufacturer’s instructions. The 
concentrations of RNA were determined by Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies, USA). The quality of extract 
total RNA was checked by loading 50ng of total RNA sample for 1% (w/v) 
agarose gel electrophoresis in TBE buffer for 1 hour. Sharp visible 18s and 
28s and absence of genomic DNA bands indicate good quality of RNA. For 
cDNA synthesis, 500ng-1000ng of total RNA per 20μl reaction volume of 
each sample was transcribed into cDNA reversely using iScript cDNA 
synthesis Kit (Bio-Rad, USA). The reaction mixture contained 4μl of 5× 
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total RNA samples and RNase-free water. The cDNA synthesis was carried 
out in thermal cycler (MycyclerTM BioRad) with the following protocol: 5 
minutes at 25°C, 30 minutes at 42°C, 5 minutes at 85°C and held at 4°C.  
For conventional PCR, the obtained cDNA samples were subjected to PCR 
amplifications for 35 cycles (Denaturing: 95°C, 30 seconds; Annealing: 55oC, 
45 seconds; Extension: 72°C, 60 seconds) followed by extra extension at 72°C 
for 10 minutes and held at 4°C in MycyclerTM. House-keeping gene β-actin 
served as the loading control.  
The real-time RT-PCR was performed on Applied Biosciences 7500 fast real 
time PCR system (Applied Biosystems). The primers used were summarized 
in Table 8. The level of relative expression of each target gene was then 
calculated as 2-ΔΔCt as described previously (Livak & Schmittgen, 2001). 
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Gene Primer Sequence (5' to 3') 
Oct4 F CGTGAAGCTGGAGGAGAAGGAGAAGCTG R AAGGGCCGCAGCTTACACATGTTC 
Nanog F GGCAAACAACCCACTTCTGC R AAGGGCCGCAGCTTACACATGTTC 
hTERT F ATGCGACAGTTCGTGGCTCA R ATCCCCTGGCACTGGACGTA 
hTERC F GCGAAGAGTTGGGCTCTGTC R CATGTGTGAGCCGAGTCCTG 
DKC1 F CATGAGGTGGTAGCCTGGAT R ACCACTGTGCCCTGTCTTCT 
CD31 F TCTATGACCTCGCCCTCCACAAA R GAACGGTGTCTTCAGGTTGGTATTTCA 
Flk F CGGCTCTTTCGCTTACTGTT R TCCTGTATGGAGGAGGAGGA 
VE-cad F AGCCCAAAGTGTGTGAGAACGC R CTGAGATGACCACGGGTAGGAA 
VWF F TTCCAGAATGGCAAGAGAGTG R TGAGTTGGCAAAGTCATAAGG 
GAPDH F GTGGACCTGACCTGCCGTCT R GGAGGAGTGGGTGTCGCTGT 
β-actin F CCAAGGCCAACCGCGAGAAGATGAC R AGGGTACATGGTGGTGCCGCCAGAC 
 
Table 2.1 Sequences of primers used for RT-PCR analysis. 
3.8 Telomere length measurement using southern blot analysis of terminal 
restrict fragments (TRF)  
The southern blot method of telomere length measurement was reported by 
(Kimura et al., 2010) and the commercial kit – TelomTAGGG telomere length 
assay – is available from Roche. The principle behind TRF method is: firstly, 
to fragmentize genomic DNA (gDNA) using restrict enzymes and to leave 
only the undigested telomere repeats fragments; next, larger telomere 
fragments were separated from other fragments using gel electrophoresis; and 
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In this study, slight modified protocol was applied: Cell samples were lysed 
and gDNA was extracted using High Pure PCR Template Preparation Kit 
(Roche) and the concentration was then determined by Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies, USA), 250ng of gDNA was used 
for the following analysis. To further ensure the quality of gDNA, 50ng of 
sample were loaded for 1% (v/w) agarose gel electrophoresis for 1-2 hours, 
sharp gDNA bands without smear was considered good quality. The gDNA 
samples were then treated with Rsa-I and Hinf-I fast digest enzyme (Thermo 
Scientific) for 20 minutes at 37oC. The digested DNA fragments were 
separated through 0.8% (w/v) agarose gel in TAE buffer at 60V for 3 hours. 
The gel was then treated with 0.25M HCl to break up DNA in the gel for 
better transfer in the following blotting step. Then, after 5 minutes washing 
with autoclaved distilled water, the gel was treated with 0.4M NaOH to 
denature the DNA in the gel. The DNA in the gel was then blotted directly to a 
positively charge nylon membrane by alkaline transfer. After transfer, the 
membrane with DNA attached was processed using telomere length assay kit 
(Roche) followed by the manufacturer’s instructions. Finally, the signals on 
membrane was detected using ChemiDoc™ MP system (Bio-rad) and 
analyzed by image lab software (Bio-rad). 
3.9 Telomerase activity analysis using real-time quantitative telomeric 
repeat amplification protocol (qTRAP) assay 
Conventional TRAP assay was introduced in 1994 (Kim et al., 1994; Harley et 
al., 1994) which incorporate conventional PCR. However, this method also 
inherited the problem of limited dynamic range as well as end-point detection 
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difficult. Moreover, the post-PCR processing is time-consuming and adds 
further variables during analysis of the PCR products. A modified real-time 
qTRAP method uses real-time qPCR to replace conventional PCR which is 
more sensitive, yet produce comparable results (Hou et al., 2001). 
Thus in this study, real-time qTRAP method was used to determine the 
telomerase activity of cell samples. Briefly, cells lysed in 0.5% (v/v) CHAPS 
buffer (pH 7.5) supplemented with 10 mM Tris-HCl, 1mM MgCl2, 1mM 
EGTA, 0.1mM benzamidine, 5mM BME, and 10% glycerol for 30 minutes on 
ice. After lysis, the samples were centrifuged for 20 minutes at 12000 × g at 
4°C to remove cell debris. The telomerase elongation reaction was carried out 
in 1× TRAP buffer (20mM Tris-HCl, pH8.3, 1.5mM MgCl2, 63mM KCl, 0.05% 
Tween20, 1mM EGTA, 0.1mg/ml BSA) and 50µM each of the four dNTPs 
and 80ng/µl TS primer (5’-AAT CCG TCG AGC AGA GTT-3’) and 8µg 
(protein amount) of cell lysate in a total volume of 40µl for 30minutes at 
30 °C and was stopped by incubation at 94 °C for 10 minutes. Next, 8.5µl of 
the elongation product, 1.5µl of ACX primer (5’-GCG CGG CTT ACC CTT 
ACC CTTACC CTA ACC-3’, 100µM) and 10µl of 2× iTaq Universal SYBR 
Green Supermix (Bio-rad) were mixed for real-time qPCR. Real-time qPCR 
experiments were carried out in triplicates. The real-time qPCR was 
performed in a CFX Connect™ Real-Time PCR Detection System (Bio-Rad) 
using conditions as follows: 10 minutes incubation at 94°C, 40 cycles of PCR 
at 94°C for 30 seconds and 60°C for 90 seconds. All results were quantified 
using CFX manager software (Bio-Rad) and telomerase activity was expressed 
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3.10 Western blot analysis  
Cells tested were washed twice with DMEM/F12 blank medium before 
lysised  cell lysis buffer (50mM Tris-HCl, pH6.8; 2% SDS, 10% Glycerol & 5% 
BME). The protein lysate was sonicated to break the gDNA and boiled for 5 
minutes at 100°C. The lysates were then electrophoresed on 10% SDS-
polyacrylamide gel and the separated proteins were transferred onto PVDF 
membrane (Bio-Rad, USA). The membrane was then blocked for 1 hour with 
5% non-fat dry milk in 1× PBS with tween (0.1% Tween 20, PBST) and 
probed with anti-β-catenin (Cell signaling Technologies, USA) and anti-non-
phosphorylated active β-catenin (Cell signaling Technologies, USA). Proteins 
of interest were detected with HRP-conjugated goat anti-rabbit IgG antibody 
(1:1000, Life Technologies) and visualized using ChemiDoc™ MP system 
(Bio-rad) and analyzed by image lab software (Bio-Rad). 
3.11 Immunofluorescent staining 
Cells were washed with 1× PBS three times and fixed with 4% neutralized 
paraformaldehyde (PFA) for 10minutes at room temperature, followed by 10 
minutes permeabilization with 0.2% Triton X-100 in PBS, the cells were 
blocked for 1 hour with 5% goat serum and 2% BSA. Diluted primary 
antibodies were then added to the culture and incubated at 4oC overnight. IgG 
isotype controls (Mouse IgG1 from R&D systems, USA; Rabbit polyclonal 
IgG from Abcam, UK) were used as control for staining respectively. After 
four washes with 1× PBS, diluted secondary antibodies against corresponding 
primary antibodies were added and incubated in dark at room temperature for 
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minutes prior final wash. Pictures were taken under fluorescent microscope 
(Olympus IX700, Tokyo, Japan). The antibodies used were listed in Table 2.2. 
Protein Target Species Company Dilution Purpose Fluorocore 
β-III tubulin 
(Tuj1) Mouse Santa Cruz 1:200 IF/FC n/a 
β-catenin Rabbit CST 1:1000 WB n/a 
Active β-catenin Rabbit CST 1:1000 WB n/a 
β-actin Rabbit CST 1:1000 WB n/a 
HRP rabbit IgG Goat Life Technologies 1:1000 WB n/a 
Mouse IgG Goat Life Technologies 1:200 IF 
Alexa 
Fluor488 
Table 2.2 List of antibodies used for analysis.  
 
3.12 Flow Cytometry analysis 
Cells were trypsinized for 5 minutes at 37oC with Trypsin EDTA (Life 
Technologies). Following 5 minutes centrifugation, cell pellets were fixed in 4% 
PFA for 10 minutes at room temperature. The cell pellets were then 
immediately chilled on ice for 1 minutes, followed by 10 minutes of 
permeabilization in 0.2% Triton X-100 in 1× PBS. Primary antibodies were 
then added to pellets and incubated at room temperature for 4 hours followed 
by secondary antibody incubation for 1 hour. Fluorescent signals were then 
read by CyAn™ Flow Cytometer (Beckman Coulter, Miami, USA). 
Approximately 10,000 cells were gated for analyzing each marker. 
3.13 MTS assay for cell proliferation 
Cell titer96® aqueous solution cell proliferation assay kit (Promega) was used 
in this study. Cells tested were seeded on ECM-coated 96-well plates at a 
seeding density of 1000/well with 200µl of medium. Cells were seeded at 





Materials and Methods 
3, 5 & 7. Culture medium was changed at Day 4 for day 5 & 7 plates. Cells 
were allowed to attach for at least overnight before MTS assay was conducted. 
At each time point, the corresponding plate was used to for MTS analysis: 
culture medium was removed from the well and 120µl MTS medium (100µl 
culture medium + 20µl MTS reagent) was added to each well and plate was 
incubated in dark at 37oC for 4 hours. Immediately after incubation, 20µl of 10% 
SDS was added to each well to stop the reaction. The plate was then analyzed 
using Infinite® 200 plate reader (Tecan group, Mannedorf, Switzerland) and 
absorbance were read at 490nm.  
3.14 Enzyme-linked Immunosorbent assay (ELISA) analysis for bFGF in 
culture media 
Human bFGF ELISA Kit (SIGMA) was used in this study. Samples with high 
concentration of bFGF were pre-diluted with DMEM/F12 blank media so that 
the final absorbance reading lied within the range of standard curve. To verify 
the exact concentration of bFGF in bFGF treatment experiments, fresh 
prepared mTeSR™1 media, hESC media, mTeSR™1 media supplemented 
with extra 100ng/ml bFGF and hESC media supplemented with extra 
100ng/ml were prepared for ELISA test. To investigate if MEF feeders 
secreted bFGF into ESC media, ESC media with and without MEF feeders 
were cultured in ESC media for 24 hours at 37oC in incubator with 5% CO2 
and 95% humidity, then used for bFGF ELISA test; a fresh ESC media sample 
were used as control. The samples were processed according to 
manufacturer’s instructions. The final solution was analyzed using Infinite® 
200 plate reader (Tecan group, Mannedorf, Switzerland) and absorbance was 
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3.15 Statistical analysis 
All statistical analyses were performed using SPSS version 18 (SPSS Inc., 
Chicago, IL, USA). Data were presented as mean ± SEM. Statistical analysis 
was by student’s t-test compared with the controls. In case of trend analysis, 



















4.1 Analysis of telomere length and telomerase function in hESC and 
hESC-differentiated cells 
4.1.1 Telomere length of hESCs in MEF feeder system and mTeSR™1 feeder-
free systems 
MEF feeder system (MEF system) and mTeSR™1 feeder free systems 
(mTeSR™1 system) were used to culture H1 and H9 hESCs. Telomere 
lengths of H1 and H9 hESCs at different passages were analyzed. The 
pluripotent markers OCT4 and Nanog, sex markers were tested through 
conventional PCR (Figure 4.1a). The primers for sex markers were designed 
to detect centromeric alphoid repeats of X and Y chromosome (Lin et al., 
1995). The telomere lengths of H1 hESCs cultured in MEF feeder system 
ranged from 9.7 kb to 9.9 kb. The changes in telomere lengths over > 50 
passages were not statistically significant (Figure 4.1b). Similarly, there was 
no significant change in telomere length in H9 hESCs cultured in MEF feeder 
system over 14 passages (Figure 4.1c). Of note, although the telomere length 
of H1 hESCs cultured in mTeSR™1 system did not differ significantly among 
different passages, the average telomere lengths of cells cultured in the 
mTeSR™1 system were significantly longer compared to those from MEF 







Figure 4.1a. Expression of pluripotency markers and sex markers in hESCs 
cultured in mTeSR™1 and MEF systems. All hESCs expressed OCT4, Nanog. 
All H1 ESCs were positive for both X and Y chromosomes while H9 ESCs 




Figure 4.1b. Analysis of telomere length of H1 hESC cultured in MEF system 
at different passage numbers. There were no significant changes in H1 ESCs’ 



























Figure 4.1c. Analysis of telomere length of H9 hESC at different passage 
number in MEF system. There were no significant changes in telomere length 





Figure 4.1d. Analysis of telomere length of different passage numbers of 
hESC in mTeSR™1 system. There were no significant changes of telomere 
length from P70 to P85 (white column). However, the average length were 
significantly longer when compared to cells cultured in MEF system (black 
















































4.1.2 hTERT is the key determinant of telomerase function in hESC 
Telomerase is composed of three major subunits - telomerase reverse 
transcriptase (TERT), telomeric RNA template (TERC) and dyskerin (DKC1). 
Unlike TERC and DKC1, which are ubiquitously expressed in all types of 
cells (Heiss et al., 1998; Feng et al., 1995), TERT is absent in somatic cells, 
and therefore a key determinant of telomerase function. TERT is expressed in 
highly self-renewing or immortalized cells such as embryonic cells, germ cells, 
cancer cells, and some adult stem cells (Cong et al., 2002). Over-expression of 
TERT in somatic cells allows replicative senescence to be overcome and 
contributes to malignant transformation (Horikawa & Barrett, 2003).  
The above observations were confirmed in this study using hESC-
differentiated embryoid body derived fibroblasts (ebFs). The TERT, TERC 
and DKC1 expression levels were analyzed using real-time qPCR. Although 
the expression of TERT, TERC and DKC1 decreased significantly in ebF as 
early as the passage 2 (Figures 4.2a-b), TERT expression, unlike the other two 
genes, was most significantly reduced to negligible level at passage 2 (Figure 
4.2d).  Thus, the expression level of TERT rather than TERC and DKC1 was 










Figure 4.2a. Real-time qPCR results of relative TERC expression in hESC and 
its differentiated ebF. Data are presented as mean±SEM, * p<0.05, compared 
to undifferentiated hESC. There was significant decreased in TERC 
expression. However, there were still significant residual TERC expression 




Figure 4.2b. Real-time qPCR results of relative DKC1 expression in hESC and 
its differentiated ebF. Data are presented as mean±SEM, * p<0.05, compared 
to undifferentiated hESC. There was significant decrease in DKC1 expression. 






























































4.1.3 Telomere length and telomerase changes in embryoid body derived 
fibroblasts (ebF)  
H1 ebFs were differentiated from H1 hESC using published protocol (Fu et al., 
2011) and cultured in ebF medium for over 18 passages. The telomere length, 
hTERT expression and telomerase activity were assessed using TRF assay, 
real-time qPCR and Q-TRAP assay. The results showed that telomere length 
started to decrease as early as P2, and continued to P18 (Figure 4.2c). hTERT 
expression (Figure 4.2d) and telomerase activity (Figure 4.2e) reduced 
significantly to negligible level as early as P2 which corroborated with the 
telomere length results, showing the inability of the cells to maintain telomere 
length. 
To characterize ebF, fibrillin 1 (FBN1) was used as a fibroblast marker in this 
study. Fibrillin is a glycoprotein, which is essential for the formation of elastic 
fibers found in connective tissue. Fibrillin is secreted into the extracellular 
matrix by fibroblasts and becomes incorporated into the insoluble microfibrils, 
which appear to provide a scaffold for deposition of elastin (Kielty et al., 
2002). Fibrillin1 is a major component of the microfibrils that form a sheath 
surrounding the amorphours elastin (Sakai et al., 1986). The real-time qPCR 
results showed a significant increase of FBN1 expression compared to 








Figure 4.2c. Telomere length change in differentiated ebFs. Telomere length 
of ebF started to decrease since P2 and continued till P18 .Data are presented 
as mean±SEM, * p<0.05 for one-way ANOVA test). 
 
 
Figure 4.2d. hTERT expression change in differentiated ebFs. Data are 
presented as mean±SEM, * p<0.05, compared to ESC sample. hTERT 



































































Figure 4.2e. Telomerase activity change in differentiated ebFs. Data are 
presented as mean ±SEM, * p<0.05, compared to ESC sample. Telomere 
activity decreased significantly to negligible level at passage 2 of 
differentiation. A negative control (NC) sample (no protein loaded) was added, 
and no significant differences between NC and ebF samples further confirms 
the TA of ebF decreased to a undetectable level. 
 
 
Figure 4.2f. Real-time qPCR results of relative FBN1 expression in hESCs 
and ebFs. Data are presented as mean±SEM, n=3, p<0.05, * compared to H1 
ESC sample. FBN1 expression increased from Passage 2 and maintained at 
high levels compared to hESC. 
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4.1.4 Critically short telomere length in ebF is associated with proliferation 
halt. 
Normal (not cancerous or immortalized, either spontaneous or modified) 
mammalian somatic cells in vitro divide a limited number of times, and the 
maximum number is called the Hayflick limit (Hayflick, 1965). At Hayflick 
limit, the telomere length is critically short and a permanent growth arrest or 
replicative senescence is triggered (Allsopp et al., 1992). In this study, we 
used ebFs to demonstrate the association of shortening or telomere and cell 
proliferation. H1 ESC derived ebF were cultured as previously published 
protocol (Fu et al., 2011) till the cells stopped growing. Cells at three different 
passages – P10, P15 & P34, were used for proliferation assay and telomere 
length measurement. The results showed a close association of telomere length 
and proliferation rate. The results confirmed the findings of previous studies 
that when telomere length is critically short, cells stopped proliferating 
(Figures 4.2g-h). 
  
Figure 4.2g. Telomere length change in differentiated H1 ebF differentiation 

































to hESC; ‡=compared to cells at earlier passage – P15 compared to P10; P34 
compared to P15. The telomere length decreased progressively from H1 ESC 
to H1 ebF P34. 
 
  
Figure 4.2h. The proliferation rate of H1 ebF at P11, P16 and P36. Data are 
presented as mean±SEM, p<0.05, * compared to P11 sample at respective 
time point and # compared to previous passage time point of same passage. 
Cellular proliferation reduced following subsequent cellular passages. At 
passage 36, H1 ebFs showed no significant growth through 7 days of culture. 
 
4.1.5 Telomere length and telomerase changes in neuron differentiation 
H9 ESCs were differentiated to neuron using the modified protocol mention in 
previous chapter (Section 3.6). Neurons at Days 20, 30 and 40 were used for 
telomere length and hTERT expression assessment. All these data showed a 
continuous decrease in telomere length due to the significant decrease in 
hTERT (Figures 4.3a-b). 
Neuron-specific class III beta-tubulin (Tuj1) was used to characterize 
differentiated neurons in this study. Anti-Tuj1 (Santa Cruz) was used in flow 
cytometry analysis as well as immune-fluorescence (IF) staining of neuron 














































differentiation and continued to express till Day 40 (Figure 4.3c). Flow 
cytometry analysis of Day 10 neuron cells corroborated with the IF results 
(Figure 4.3d). 
 
Figure 4.3a. Telomere length of hESC and differentiated neuron. Data are 
presented as mean±SEM, n=2, compare to H9 ESC sample, * p<0.05. The 
telomere length decreased from 10.21kb to 9.19kb after 40 days of 
differentiation. 
 
Figure 4.3b. Real-time qPCR results of relative hTERT expression of neurons. 
Data are presented as mean±SEM, n=3, p<0.05, compared to H9 ESC sample. 






















































Figure 4.3c. Flow cytometric analysis of differentiated neuron at Day10. 99.9% 
of cells were positive for neuron marker Tuj1. 
 
Figure 4.3d. Immuno-fluorescence staining for neurons at Days 5, 10 and 40 
of differentiation (Blue for DAPI staining and green for Tuj1 staining). Cells 
at all above time points were positive for neuron marker Tuj1. 
 
 






4.1.6 Telomere length and telomerase changes in keratinocyte differentiation 
H9 ESCs were differentiated to keratinocyte using the published protocol 
(Kidwai et al., 2013), the details of differentiation were mentioned in previous 
chapter (Section 3.4). Keratinocyte were cultured in keratinocyte serum free 
medium (KSFM, Life Technologies) till P10. Cells were harvest every 2-3 
passages for telomere length and hTERT expression analysis. The results 
(Figures 4.4a-b) showed a continuous decease of telomere length and 
significant drop in hTERT expression since the beginning of differentiation. 
In order to characterize keratinocyte features, real-time qPCR analysis of 
keratin 14 (K14) and delta Np63 (∆Np63) were applied. K14 is a member of 
the type I keratin family of intermediate filament proteins, which is usually 
found as a heterodimer with type II keratin 5 and form the cytoskeleton of 
epithelial cells (Schweizer et al., 2006). Whereas ∆Np63 is essential for 
normal epidermal stratification and the proliferative potential of the epithelial 
stem cells (Leonard et al., 2011; Mills et al., 1999; Yang et al., 1999; McKeon, 
2004). The results showed significant increase of these two genes in 








Figure 4.4a. Telomere length change of differentiated keratinocyte. Data are 
presented as mean±SEM. The telomere length decreases gradually from 
13.8kb to 10.5kb from H9 ESC to P10 Keratinocyte (Black columns, * p<0.05 
for one-way ANOVA test). Last white column was telomere length of an 
immortal human keratinocyte cell line as comparison. 
 
 
Figure 4.4b. Real-time qPCR results of relative hTERT expression in hESCs 
and differentiated keratinocytes. Data are presented as mean±SEM, n=3, 
p<0.05 compared with undifferentiated hESC sample. hTERT expression 
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Figure 4.4c. Real-time qPCR results of relative expression of keratinocyte 
makers – K14 & ΔNp63 in hESC and differentiated keratinocytes. Data are 
presented as mean±SEM, p<0.05, compared with H1 ESC sample. Both K14 
and ΔNp63 were significantly increased in keratinocytes compared to 
undifferentiated ESCs. 
 
4.1.7 Telomere length and telomerase change in endothelial cell 
differentiation 
H1 ESCs were differentiated into endothelial cells using published protocol 
(Tan et al., 2013), the details of differentiation were mentioned in previous 
chapter (Section 3.5). Endothelial cells were harvested at different passages 
between P0 to P9. Genomic DNA and total RNA were extracted for telomere 
length and hTERT expression analysis. Similarly, telomere length decreased 
along the differentiation process (Figure 4.5a), and hTERT expression 
decreased to minimum level as early as since Passage 1 (Figure 4.5b).  
Four typical endothelial markers: Flk, CD31, vascular endothelial-cadherin 
(VE-cad) and VWF were analyzed, to characterize the differentiated 









































Figure 4.5a. The telomere length change in differentiated endothelial cells. 
Data are presented as mean±SEM, * p<0.05 for one-way ANOVA trend test. 
Telomere length decreased progressively from 12.7kb in hESC to 8.1kb at 
Passage 9 of endothelial cells. 
 
 
Figure 4.5b. Real-time qPCR results of relative hTERT expression in hESC 
and differentiated endothelial cells. Data are presented as mean±SEM, n=3, * 
p<0.05, compared to undifferentiated hESC. hTERT expression dropped to 5% 
of the level in hESC at P0, and further to bottom level since P1. There is no 























































Figure 4.5c. Real-time qPCR results of endothelial markers – Flk, CD31, VE-
cad & VWF expression in hESC and differentiated endothelial cells. Data are 
presented as mean±SEM, * p<0.05, compared to H1 ESC sample. The 
endothelial markers boosted up since P1 of differentiation and continued to P9. 
 
4.2 Investigation of telomere length variation of hESC in different culture 
systems 
4.2.1 Swopping the culture systems affected telomere length of H1 ESCs 
In order to confirm whether the culture conditions can results in differences in 
telomere length, short-telomere (~11.5kb) H1 ESCs originally cultured in 
MEF system was transferred to mTeSR™1 system, while long-telomere 
(~17.3kb) H1 ESCs originally cultured in mTeSR™1 system was transferred 
to MEF system. Telomere length from both cell populations was examined 
after about 5 passages and 11 passages. Genomic DNA was extracted and 
telomere length was measured. It was found that the telomere length of H1 
ESCs, which possessed shorter telomere length, became longer (from 11.5kb 
to 15.3kb) when transferred from MEF to mTeSR™1 culture system. On the 



































































mTeSR™1 to MEF culture system, the telomere shortened significantly from 
17.3kb to 15.7kb (Figure 4.6a). 
 
Figure 4.6a. The telomere length change of H1 hESC when culture systems 
were swopped. Data are presented as mean±SEM, p<0.05, * = compare to 1st 
passage; ‡=compare to previous time point. When H1 ESCs were transferred 
from mTeSR™1 feeder free system to MEF feeder system (white column), the 
telomere length shortened gradually from 17.3kb to 15.7kb, 12 passages after 
the transfer. In contrast, When H1 ESCs cultured in MEF feeder system were 
transferred to mTeSR™1 feeder free system, the telomere length increased 
from 11.5kb to 15.3kb after 11 passages. 
 
 4.2.2 bFGF played a role in hESC telomere length maintenance 
Previous data confirmed that the hESC culture systems played a crucial role in 
hESC’s telomere length maintenance. By comparing the components of the 
three hESC culture systems - mTeSR™1 system, MEF system and MEF 
conditioned medium (CM) system (Table 4.1), it was found that most 
components were identical except three, namely, bFGF, TGFβ and LiCl. In the 
mTeSR™1 culture system, bFGF is 25 times more than in MEF system and 
MEF CM system (100ng/ml vs. 4ng/ml); moreover, TGFβ and LiCl are absent 














































addressed the potential links between TGFβ and telomere or telomerase in 
hESC culture. One study have shown that TGFβ stabilizes the pluripotency in 
hESC culture (Averyet al., 2010), and other studies showed TGFβ to suppress 
hTERT in some cancer cells (Li et al., 2006). LiCl was reported to increase 
hTERT expression as well as telomerase activity in cancer cell lines (Zhang et 
al., 2012); however, no related studies have been carried out in hESCs. 
Furthermore, both TGFβ and LiCl was removed in mTeSR™1’s successor 
medium – TeSR-E8 indicating that it was not essential for hESC maintenance 
(Chen et al., 2011). To test whether TGFβ or LiCl affects hTERT in hESC, 
cells were cultured 24 hours in MEF CM system supplemented with TGFβ and 
LiCl at concentrations similar to those in mTeSR™1 system. Results showed 
no significant change in hTERT expression of hESCs cultured in MEF CM 








DMEM F12 80% 80% 80% 
bFGF 100ng/ml * 4ng/ml 4ng/ml 
L-Glutamine 1% (v/v) 1% (v/v) 1% (v/v) 
2-Mercaptoethanol 
(BME) 
1mM 1mM 1mM 
Knockout Serum 
Replacement 
20% (v/v) 20% (v/v) 20% (v/v) 
LiCl 1mM † No No 
TGF-β 0.6ng/ml‡ No No 
Matrigel™ coating Yes No Yes 
MEF feeders No Yes No 
 
Table 4.1. Comparison of three different hESC culture systems – mTeSR™1 
feeder free system, MEF feeder system & MEF conditioned medium feeder 
free system. Most components are identical except the concentration of bFGF 










Figure 4.6b. Real-time qPCR results of relative hTERT expression after 24 
hours of 1mM LiCl treatment to H1 hESC. Data are presented as mean±SEM. 
There was no significant change of hTERT expression after being treated with 




Figure 4.6c. Real-time qPCR results of relative hTERT expression after 
0.6ng/ml TGFβ treatment to H1 hESC Data are presented as mean±SEM. 
There is no significant change after 24 hours treatment of 0.6ng/ml TGFβ. 
 
Thus, we focused on the effect of bFGF on telomere length in this study. 
Firstly, we verified the basal level of bFGF in mTeSR™1 system medium 
(mTeSR™1 medium) and MEF system medium (hESC medium) using bFGF 















































and hESC medium when extra bFGF (100ng/ml) was added (Figure 4.6d). The 
results confirmed that the bFGF concentration in mTeSR™1 system and MEF 
system. In addition, the results showed that when exogenous bFGF (100ng/ml) 
was added into hESC medium, the bFGF level was similar to those found in 
the mTeSR™1 medium. In order to find out if MEF feeders secrete bFGF 
during hESC culture, we measured the bFGF level of hESC media in which 
MEF feeders had been cultured for 24 hours (37oC, 5% CO2 and 95% 
humidity), while hESC without MEF feeders was incubated at the same time 
under same condition as control. No significant difference in bFGF level was 
found in hESC media with or without MEF feeders, which suggested that 
MEF did not secrete detectable bFGF in MEF system. However, by comparing 
these data with fresh hESC medium, it was found that there was significant 
decrease of bFGF concentration in hESC medium after 24 hours of incubation 
- with or without MEF feeders, indicating a degradation of bFGF in 24-hour 
normal culture (37oC, 5% CO2 & 95% humidity) (Figure 4.6e). Similar data 
was reported in previous studies (Lotz et al., 2013).  
All above results confirmed that fresh mTeSR™1 media contained about 
100ng/ml bFGF, fresh hESC media contained about 4ng/ml bFGF; fresh hESC 
media which supplemented with extra bFGF had a matching level of bFGF of 
about 100ng/ml compared to fresh mTeSR™1 media; MEF feeders did not 








Figure 4.6d. ELISA analysis of bFGF concentration in different ESC medium. 
Data are presented as mean±SEM, n=3, p<0.05, * = compared to ESC medium, 
†= compare to mTeSR™1 medium. The results confirmed the difference of 
bFGF concentration in MEF system and mTeSR™1 system. When extra bFGF 
was added to ESC medium, the detected bFGF concentration is comparable to 
mTeSR™1 medium. When extra bFGF was added to mTeSR™1 medium, 
significant increase of bFGF level is noticed. 
 
 
Figure 4.6e. ELISA analysis of bFGF degradation in ESC medium and MEF’s 
contribution of bFGF concentration. Data are presented as mean±SEM, n=3, 
p<0.05, * = compared to fresh ESC medium. The results confirmed the 
degradation of bFGF after 24-hour incubation in medium without any cells. 























There was no significant difference between ESC media and ESC 
media+MEFs after 24-hour incubation, indicating that MEFs in MEF system 
and MEF CM system did not secrete detectable amount of bFGF. 
 
To investigate the effect of bFGF on telomere length, extra bFGF (100ng/ml) 
was added to mTeSR™1 medium in swopping experiment, telomere length 
were then measured after 5-9 passages. H1 ESCs from MEF feeder system 
were used as starting point, cells were transferred in mTeSR™1 system as 
control; extra 100ng/ml bFGF were added to mTeSR™1 medium as treatment 
group. Similar to previous results, telomere of H1 ESCs lengthened after being 
transferred from MEF system to mTeSR™1 system. Surprisingly, in bFGF 
treatment group, the lengthening of telomere was significantly greater than 
control group (Figures 6f).  
 
  
Figure 4.6f. The telomere length change of H1 ESCs transferred from MEF 
feeder system to mTeSR™1 feeder free system and treated with extra bFGF 
(100ng/ml). Data are presented as mean±SEM, *p<0.05, compared to H1 P59 
before swopping. Without extra bFGF, the telomere length of H1 ESCs 
increased from 11kb to 13.9kb gradually after 9 passages; however, with extra 
bFGF added, the telomere length increased at faster rate to a final length of 










































Previous results (Section 4.2.1) showed that when H1 ESCs was transferred 
from low bFGF containing MEF system to high bFGF containing mTeSR™1 
system, telomere lengthened; and telomere shortened if H1 ESCs were 
transferred from mTeSR™1 system to MEF system. Similar experiment was 
repeated between mTeSR™1 system and MEF CM system, telomere length 
were measured 5 passages after hESCs were transferred from mTeSR™1 
system to MEF CM system. The results showed significant decrease in 
telomere length (Figure 4.6h). 
  
Figure 4.6g. The telomere length change of H1 ESCs transferred from 
mTeSR™1 feeder free system to MEF CM system. Data are presented as 
mean±SEM, *p<0.05. The telomere length of H1 ESCs significantly decreased 
from 12.8kb to 11.0kb, 4 passages after being transferred to CM system; while 
the telomere maintain in mTeSR™1 didn’t change significantly. 
 
To further confirm that it is bFGF but not other component absent in the MEF 
CM system was responsible for the shortening of telomere length, exogenous 
bFGF was added in MEF CM system to match 100ng/ml concentration in 
mTeSR™1 system. Similar experiment was carried out, H1 ESCs were 





























bFGF medium. After 5 passages of parallel treatment, there was significant 
decrease of telomere length of ESCs that were transferred from mTeSR™1 
medium to MEF CM system; however, for those transferred from mTeSR 
medium to in MEF CM + bFGF medium, the shortening of telomere length 
was rescued and no significant change in telomere length was found compare 
to those in mTeSR™1 system (Figure 4.6h). 
 
 
Figure 4.6h. The telomere length change of H1 ESCs transferred from 
mTeSR™1 feeder free system to MEF CM system and with bFGF treatment 
(100ng/ml). Data are presented as mean±SEM, * p<0.05 compared to H1 P104 
in mTeSR™1. After 5 passages, telomere of H1 ESCs in CM significantly 
decreased from 9.1kb to 8.3kb. However, with bFGF added in CM, the 




4.2.3 hTERT expression and telomere activity accompanied telomere length 
changes. 
Since previous data showed bFGF treatment significantly changed telomere 
length in hESCs, the next step was to find out if telomere length increase was 

































(Figure 4.6f-g) were used and total RNA and total protein were extracted for 
real-time qPCR and Q-TRAP assay. The results showed there was significant 
increase in both 5 passages and 10 passages of bFGF treatment (Figures 4.6i-j). 
Telomerase activity also increased when cells were treated with bFGF for 5 
passages (Figure 4.6k). 
 
Figure 4.6i. Real-time qPCR results of relative hTERT expression after 5 
passages of bFGF treatment (100ng/ml). Data are presented as mean±SEM, 
n=3, p<0.05. hTERT expression increased significantly after bFGF treatment 
for 5 consecutive passages.  
 
 
Figure 4.6j. Real-time qPCR results of relative hTERT expression after 10 





















































n=3, p<0.05. There was significant increase in hTERT expression after 10 




Figure 4.6l. Telomerase activity of H1 ESC after 5 passages of bFGF 
treatment (100ng/ml). Data presented as mean±SEM, n=3, p<0.05, * 
compared to non-treated hESCs. There is significant increase of telomerase 
activity after bFGF treatment for 5 passages. 
 
4.2.4 Short-term treatment of bFGF also up-regulates telomerase 
The change of telomere length was only detectable over long period (more 
than 5 passages in this study); experiments were carried out to find out if 
bFGF treatment could also increase TERT expression and telomerase activity 
(TA) in shorter period of time. H1 ESCs cultured in mTeSR™1 system were 
treated with exogenous bFGF (100ng/ml) for 24 hours and TERT expression 
and TA were analyzed. The results shows similar increase of TERT expression 
and TA (Figure 4.7a-d), indicating that hTERT and TA responded to bFGF 
treatment within 24 hours. Pluripotency markers OCT4 and Nanog were also 
examined, and the results show no significant change in pluripotency markers 



































Figure 4.7a. Real-time qPCR results of relative hTERT expression after bFGF 
treatment for 24hrs and 48hrs in mTeSR™1. Data are presented as 
mean±SEM, n=3, p<0.05, * compared to respective control samples. hTERT 






Figure 4.7b. TA change after 24 hours of bFGF treatment in mTeSR™1. Data 
are presented as mean±SEM, n=3, p<0.05, * compared to non-treated hESCs. 
























































 Figure 4.7c. hTERT expression after bFGF treatment for 24hrs and 48hrs in 
MEF CM system. Data are presented as mean±SEM n=3, p<0.05, compared to 
non-treated hESCs. hTERT expression increased significantly after bFGF 




Figure 4.7d. TA change after 24 hours of bFGF treatment in MEF CM system. 
Data presented as mean±SEM, p<0.05,* compared with non-treated hESCs. 
























































Figure 4.7e. Real-time qPCR results of relative OCT4 expression after 24 
hours of bFGF treatment. Data are presented as mean±SEM, n=3. There is no 







Figure 4.7f. Real-time qPCR results of relative Nanog expression after 24 
hours of bFGF treatment. Data presented as mean±SEM. There is no 
























































4.3 Exploring the possible mechanism of bFGF’s effect on telomere and 
telomerase. 
4.3.1 Crosstalk of bFGF pathway and Wnt/β-catenin pathway 
There are many studies which have shown the involvement of the Wnt/β-
catenin signaling pathway (canonical Wnt signaling pathway) in bFGF treated 
cells (Ding et al., 2010). Additionally, other studies have shown Wnt/β-catenin 
signaling pathway to modulate TERT (Zhang et al., 2012; Greider, 2012). This 
led us to hypothesize that bFGF could affect telomere and telomerase through 
Wnt/β-catenin signaling pathway.  
To test this hypothesis, we firstly confirmed the effect of bFGF on Wnt/β-
catenin signaling pathway. The activation of Wnt/β-catenin pathway involves 
accumulation of β-catenin in the cytoplasm and eventually translocation into 
the nucleus to perform the role of transcriptional co-activator of Lef/Tcf 
transcription factor. Upon activation of Wnt/β-catenin signaling pathway, non-
phosphorylated form – also known as active form of β-catenin will be 
transported to the nucleus; on the other hand, inactivated Wnt/β-catenin 
signaling pathway produces phosphorylated β-catenin which will be sent for 
ubiquitination and degradation (Novak & Dedhar, 1999). Thus, detection the 
ratio of active/total β-catenin gives a clue of how much Wnt/β-catenin 
signaling pathway is activated (van Noort et al., 2002). 
Total proteins were extracted from tested cells and western blot was 
performed using two distinctive antibodies against active β-catenin and total β-
catenin. The ratio of active β-catenin/total β-catenin was calculated from 






catenin signaling pathway suppressor DKK1 (50ng/ml) or activator Wnt3a 
(100ng/ml) for 24 hours, the ratio of active β-catenin significantly decreased 
or increased accordingly compared to non-treated sample, indicating that 
Wnt/β-catenin signaling pathway was activated or suppressed accordingly. In 
addition, when Wnt3a was added to DKK1 treatment group, the active β-
catenin ratio significantly increased compared to DKK1 treatment alone, 
indicating that addition of Wnt3a neutralized the suppression effect of DKK1. 
Finally, when H1 hESCs were treated with bFGF (100ng/ml), the ratio of 
active/total β-catenin significantly increased compared to non-treated control; 
furthermore, when bFGF was added to DKK1 treatment group, the active/total 
β-catenin ratio also significantly increased compared to DKK1 treatment alone. 
All these results indicated that bFGF could effectively upregulate Wnt/β-
catenin signaling pathway in hESCs(Figures 4.8a-b). 
 
 
Figure 4.8a. Westernblot analysis of active/total β-catenin in hESCs after 
treatment with Wnt3a, DKK1 and bFGF. The relative amount of active and 
total β-catenin was calculated through the measurements of intensity of the 








Figure 4.8b. Change of active β-catenin/total β-catenin ratio after 24 hours of 
Wnt/β-catenin signaling pathway manipulation. Data are presented as 
mean±SEM, p<0.05, * = compared to non-treated control, † = compared to 
DKK1 treatme nt alone. Wnt activator and inhibitor - Wnt3a and DKK1 could 
significantly increase or decrease Wnt/β-catenin signaling pathway. Wnt3a 
can also neutralize the suppression effect of DKK1. Similarly, bFGF treatment 
could also significantly increase the Wnt/β-catenin signaling pathway and 
rescue the suppression effect of DKK1.  
 
4.3.2 Wnt signaling pathway affects hTERT expression and telomerase activity 
We then investigate whether activation or inhibition of Wnt/β-catenin 
signaling pathway would actually affect the hTERT expression and telomerase 
activity. H1 ESCs were treated with Wnt activator Wnt3a and inhibitor DKK1 
to see if TERT or TA is affected accordingly. When Wnt signaling pathway 
was activated using Wnt3a, the hTERT expression and TA increased 
significantly than the untreated (Figure 4.8c); in contrast, when treated with 
Wnt inhibitor DKK1, the hTERT expression and TA decreased significantly 
(Figure 4.8d). Furthermore, when bFGF was added together with DKK1, the 
decreasing of hTERT expression was partially rescued (Figure 4.8d). Similar 














































increased TA while DKK1 caused decrease of TA; and addition of bFGF 
could counter-act the effect of DKK1 (Figure 4.8e). 
 
Figure 4.8c. Real-time qPCR results of relative hTERT expression after Wnt 
activation. Data are presented as mean±SEM, * p<0.05, compared with non-
treated control. The addition of Wnt3a caused the increase of hTERT 
expression proved that activation of Wnt/β-catenin pathway was associated 
upregulate hTERT expression. 
 
 
Figure 4.8d. Real-time qPCR results of relative hTERT expression after 
DKK1 treatment. Data are presented as mean±SEM, p<0.05, *=compare to 
control, †=compare to DKK1 treatment. Blocking Wnt/β-catenin pathway 
using DKK1 (20ng/ml) for 24 hours significantly decrease hTERT. When 
























































expression was rescued partially; indicating downregulation of Wnt/β-catenin 
pathway was associated with decreasing of hTERT expression.  
 
 
Figure 4.8e. Relative telomerase activity after Wnt pathway manipulation. 
Data are presented as mean±SEM, p<0.05, *=compare to control, †=compare 
to DKK1 treatment. DKK1 can efficiently decrease TA, while both bFGF and 
Wnt3a can significantly increase TA, and counter-act the inhibition effect of 
DKK1 on TA. 
 
4.4 The telomere length of hESC can be inherited by progeny cells 
To investigate whether property of telomere length can be passed on from 
origin hESC to progeny cells, H1 ESCs of long telomere (~13kb) and short 
telomere (~8.5kb) were differentiated to ebFs at the same time using same 
protocol mentioned in previous chapter (Section 3.3). Cells were harvested in 
different passages and telomere length was measured using TRF method. The 
results showed similar fashion of telomere shortening as shown in Section 
4.1.3. As expected, ebFs differentiated from long telomere H1 hESC 
maintained longer telomere compared to ebFs differentiated from short 




































Figure 4.9a. Telomere length change of ebFs differentiated from H1 ESCs that 
have long telomere (white columns) and short telomere (black columns). Data 
are presented as mean±SEM, * p<0.05 for one-way ANOVA trend test. Long-
telomere hESCs (ESC-L) differentiated into ebFs with longer telomere (ebF-L) 
compared to those from short-telomere hESCs (ESC-S). ebFs with longer 
telomere (ebF-L) maintained their advantage over their short-telomere counter 






























































5.1 Telomerase and telomere change in hESC differentiation 
Telomeres which are guanine-rich tandem DNA repeats of the chromosomal 
end, provide chromosomal stability, and cellular replication causes their loss 
(Greider & Blackburn, 1985; Levy et al., 1992). Telomerase is consist of three 
major subunits namely telomerase reverse transcriptase (TERT), telomeric 
RNA template (TERC) and dyskerin (DKC1). Unlike TERC and DKC1, 
which are ubiquitously expressed in all types of cells (Heiss et al., 1998; Feng 
et al., 1995), TERT is present only in telomerase-positive cells but absent in 
telomerase-negative cells. Therefore, TERT is a key determinant of telomerase 
activity, which is the ability to add tandem telomeric repeats of nucleotides to 
the chromosome end (Greider & Blackburn, 1985). 
Previous studies demonstrated that hESCs can be differentiated into cells from 
all three germ layers (Golebiewska et al., 2009). However, telomerase activity 
and telomere changes in these hESC derived cells have not been well studied. 
5.1.1 TERT expression and telomerase activity decreased rapidly during 
differentiation 
In somatic cells, the activity of telomerase, a reverse transcriptase that can 
elongate telomeric repeats, is usually diminished after birth so that the 
telomere length is gradually shortened with cell divisions, and triggers cellular 
senescence. In hESCs, telomerase is activated and maintains telomere length 
and cellular immortality. However, the level of telomerase activity is low or 
absent in the majority of other stem cells regardless of their proliferative 






telomerase activity is usually strictly regulated in human body and high 
telomerase activity is not a feature of normal somatic cells. 
In previous investigations, it was shown that telomerase activity and hTERT 
expression were downregualated to a much lower level or even absent, during 
differentiation from hESCs to neural cells (Golebiewska et al., 2009) and 
hematopoietic cells (Armstrong et al., 2005). The differentiation of hESCs to 
somatic cells is similar to the development from fertilized egg to a grown 
individual. They both start from one single undifferentiated cell, and 
differentiate into all types of other cells. Some studies showed cells from early 
human embryonic tissue (e.g. human embryonic lung fibroblasts, human 
newborn foreskin fibroblasts) also had much lower TERT compared to hESCs 
(Wang et al., 2009; Armstrong et al., 2005). 
In this study, we demonstrated that telomerase activity and hTERT expression 
were downregualated to a much lower level or even absent during 
differentiation from hESCs to fibroblasts (ebFs), keratinocytes, endothelial 
cells and neuron cells. Telomerase activity and hTERT expression were found 
to decrease rapidly at very early stage of differentiation and remained at very 
low level in later expansion. Notably, in ebF and endothelial differentiation, 
the RT-qPCR results showed hTERT expression dropped to much lower level 
and telomerase activity was almost non-detectable since the first passage of 
cells. 
In summary, when hESCs differentiated into somatic cells, their high hTERT 






very early stage of differentiation and this was irreversible in the later 
expansion.    
5.1.2 Telomere shortened progressively in the absence of telomerase function 
Telomerase is responsible for telomere elongation (Greider & Blackburn, 1985) 
and end-replication problem causes cells to lose their telomere (Watson, 1972). 
A balance is kept between these two mechanisms so that hESCs can maintain 
their unlimited self-renewal and long telomere length. However, when 
telomerase activity became absent during differentiation, this balance was 
upset; replicative telomere erosion took dominance and caused the telomere to 
shorten. Unlike the sudden decrease of hTERT expression and telomerase 
activity found in hESC differentiation, the telomere shortened in a progressive 
and gradual manner in prolonged culture. This confirmed the telomere 
shortening during hESC differentiation and later expansion was mainly caused 
by end-replication problem (Watson, 1972; Levy et al., 1992), other than 
chromosome recombination which usually caused sudden change of telomere 
length in a very short time (Murnane et al., 1994). Moreover, the time when 
telomere start to shorten matched the time of rapid decrease of hTERT 
expression and telomerase activity.  
From a different point of view, the observation of telomerase activity decrease 
and telomere shortening in hESCs differentiation in turn provided us a clue of 
how important telomerase activity is in telomere maintenance of hESCs. 
Human ESCs are famous for its unlimited self-renewal and fast proliferations, 






same time, to maintain long telomere length, high telomerase activity is indeed 
indispensible in hESCs.  
5.1.3 Critical telomere length associated with cellular ageing in hESC derived 
cells 
Without telomerase activity, telomere shortening was observed in prolonged 
cell culture in vitro as well as increased age in vivo (Lindsey et al., 1991; 
Hastie et al., 1990; Harley et al., 1990; de Lange et al., 1990). A permanent 
growth arrest or replicative senescence are often associated with critical short 
telomere (Wright et al., 1989; Olovnikov, 1971; Counter et al., 1992; Hande et 
al., 1999; Blasco et al., 1997; Allsopp et al., 1992). 
In this study, we demonstrated the association of decreased proliferation and 
shortened telomere using H1 ebFs. When H1 ebFs were subjected to 
prolonged cultured in vitro, the proliferation rate decreased while telomere 
shortened. Growth arrest was observed in H1 ebFs which has critical short 
telomere of about 5kb (Section 4.1.4).  
The results indicated that cells derived from hESCs were subject to inevitable 
telomere shortening and cellular senescence just like normal somatic cells in 
human body. Since hESC has great potential in regenerative medicine, we 
hypothesized that it may be advantagerous to produce cells from hESCs that 
are less susceptible to cellular senescence.  
Since telomere length shortening cannot be avoided or reversed in hESC 
derived cells and critical short telomere length directly leads to cellular 






the beginning of differentiation, which could depend on the telomere length of 
the source hESC.  
5.2 An assessment of telomere length of hESCs 
To answer the question whether telomere length of hESCs can be altered – 
preferably elongated, it is necessary for us to identify the range of telomere 
length in hESCs. Many groups mentioned their measurement of hESCs 
telomere length in their studies, although their studies did not actually focus 
on hESC telomere length. Turner et al. reported that the telomere length of 
human blastocyst from which hESC is derived from is 12.22kb (Turner et al., 
2010). Forsyth and coworkers mentioned in their studies that the telomere 
length of hESCs they used is 12.5kb (H1) and 10.4kb (H9) (Forsyth & 
McWhir, 2008). A survey of 96 hESCs cell lines was done by Zeng et al., and 
they concluded that telomere length of these hESC is 12.02±1.01kb (Zeng et 
al., 2014). Amit and coworkers also found similar results that their H9 hESCs 
maintained their telomere between 8kb and 12kb (Amit et al., 2000). However, 
it is necessary to note that in all above mentioned studies, hESCs were 
cultured in MEF feeder system. 
5.2.1 hESCs in mTeSR™1 culture systems have longer telomere 
After investigating the telomere length of hESCs in this study, it was found 
quite interestingly that the same batch of H1 hESCs cultured in mTeSR™1 
system exhibited significant longer average telomere (~14kb to ~16kb) 
compared to those cultured in MEF feeder system (~8kb to ~12kb). To the 
best of our knowledge, to date no study has surveyed the telomere length of 






cultured in mTeSR™1 reported in this study was significantly longer than 
those reported elsewhere in MEF system, while hESCs cultured in MEF feeder 
system possessed telomere lengths consistent with previous reported data 
(Turner et al., 2010; Forsyth et al., 2008; Zeng et al., 2014; Amit et al., 2000). 
A simple validation experiment was carried out immediately to further 
confirm the above observation where H1 hESCs cultured in both culture 
systems were swopped to the other system and telomere length change were 
monitored. It was found that the telomere length of H1 ESCs, which possessed 
shorter telomere length, became longer (from 11.5kb to 15.3kb) when 
transferred from MEF to mTeSR™1 culture system. On the contrary, when H1 
ESCs with longer telomere were transferred from mTeSR™1 to MEF culture 
system, the telomere shortened significantly from 17.3kb to 15.7kb. 
The results in this study strongly suggested that the difference of culture 
systems might cause telomere length differences in hESCs. 
5.2.2 bFGF influenced the hTERT expression, telomerase activity and 
telomere length in hESC 
By comparing the components of the two culture systems, several differences 
were identified (Table 1, Section 4.2.2). Besides the presence of MEF feeders, 
TGFβ and LiCl are absent in MEF feeder system, and the concentration of 
bFGF is significantly lower in MEF feeder system compared to the mTeSR™1 
system (4ng/ml vs. 100ng/ml).  
To date, there have been few studies investigating the role of TGFβ in 
telomere or telomerase in hESC culture, though there have been studies which 






2010), and suppresses of hTERT in some cancer cells (Li et al., 2006). There 
are currently no studies connects TGFβ to either hTERT expression or 
telomere maintenance in hESCs. 
For LiCl, evidences had been shown to increase hTERT expression as well as 
telomerase activity in somatic cells and cancer cells (Kurz et al., 2003; Haïk et 
al., 2000; Zhang et al., 2012); However, the effects of LiCl on hTERT 
expression in hESC is currently unknown.  
Interestingly, LiCl and TGFβ were removed from mTeSR™1’s successor 
medium (TeSR-E8, STEMCELL Technologies), the medium was still able to 
sustain the maintenance of hESC indicating that both LiCl and TGFβ are not 
crucial for hESC maintenance (Chen et al., 2011). 
As for bFGF, it is an essential component in hESC culture medium since the 
first hESC line was established. Many studies confirmed the roles of bFGF in 
maintaining the pluripotency and self-renewal (Amit et al., 2000; Levenstein 
et al., 2006; Xu et al., 2001), there is so far no report on the role of bFGF on 
telomere or telomerase in hESCs. However, there have been studies which 
have shown associations between bFGF and TERT expression in other cell 
types, e.g. human endothelial cells, neural precursor cells, human fetal 
fibroblast cells, synoviocytes, retinoblastoma cells (Kurz et al., 2003; Haïk et 
al., 2000; Jin et al., 2010; Tsumuki et al., 2000; Kondo et al., 2001). 
In this study, we tested if TGFβ or LiCl affects hTERT expression in hESC by 
culturing hESCs for 24 hours in MEF CM system supplemented with TGFβ 






showed no significant change in hTERT expression of hESCs cultured in MEF 
CM system supplemented with TGFβ and LiCl (Section 4.2.2).  
However, we found that when hESCs in MEF CM system were treated with 
100ng/ml bFGF, which was equivalent to mTeSR™1 system, for 24 hours, 
hTERT expression was found increasing. Q-TRAP assay further validated that 
100ng/ml bFGF treatment also increased the telomerase activity within 24 
hours. All these results suggested that bFGF might affect hTERT expression 
and telomerase activity in hESCs.  
Since our initial observation is that different culture systems caused telomere 
length differences. Telomerase activity did not represent actual telomere 
length change, probably because 24-hours treatment was too short to notice 
the change of telomere, thus longer treatment was conducted in MEF CM 
system. Interestingly, results showed significant difference of telomere length 
emerges after 5 passages of culture. With extra bFGF, telomere length 
elongated about 1-2 kb within 5 passages, 2-3kb within 9 passages (Section 
4.2.2). Such results were not reported in hESC related studies before and this 
flexibility of telomere length in hESCs was not expected. 
To confirm the results, we also repeated the experiment in mTeSR™1 system 
which is more defined system by increasing bFGF concentration from to its 
basal level of 100ng/ml to 200ng/ml. We did not expect obvious change due to 
the high basal level of bFGF in mTeSR™1 medium but unexpectedly, hESCs 
treated with extra bFGF also showed faster telomere growth within 5 passages 
(Section 4.2.2). Increase of telomerase activity and hTERT expression were 






We have shown that when hESCs were moved from mTeSR™1 system to 
MEF system (Section 4.2.1) and MEF CM system (Section 4.2.2), telomere 
was found shortened. However, when bFGF was topped up in MEF CM 
system to the same concentration as in mTeSR™1 system, no shortening of 
telomere was observed after 5 passages of culture. This further confirmed that 
it was the concentration of bFGF in culture medium, but not other components 
cause the change of hTERT, telomerase activity and telomere length in hESCs 
(Section 4.2.2). 
Notably, in all above bFGF treatment experiments, the expression level of 
pluripotency markers stayed unchanged, indicating that the extra bFGF 
treatment did not alter the pluripotency of hESCs. 
In summary, we found for the first time that, (i) exogenous bFGF treatment 
had positive effect on hTERT express and telomerase activity in hESCs and, 
(ii) exogenous bFGF treatment could cause elongation of telomere in hESCs, 
possibly via the increased telomerase activity. 
5.3 Crosstalk between FGF signaling pathway and Wnt signaling pathway 
In this study, we showed that bFGF treatment could significantly increase the 
telomerase activity as well as telomere length in hESCs. However, so far there 
have been few studies investigating the potential links between FGF signaling 
pathway with telomere length in hESCs. There are however studies which 
have reported association between bFGF signaling pathway with TERT 
expression in other cell types (Kurz et al., 2003; Haïk et al., 2000; Jin et al., 
2010; Tsumuki et al., 2000; Kondo et al., 2001). Many studies have shown the 






1996; Park et al., 2009; Bilsland et al., 2009; Mukherjee et al., 2011). It was 
even shown that the TERT is a direct target of β-catenin (Zhang et al., 2012). 
β-catenin was also detected at the transcriptional start site of TERT in hESCs 
which indicate that β-catenin might play a role in TERT promoter regulation 
(Hoffmeyer et al., 2012). 
Furthermore, there have been studies describing crosstalk between FGF 
signaling and Wnt signaling. One study demonstrated in hESCs that FGF 
signaling might influence the Wnt/β-catenin pathway by downregulate GSK3β. 
GSK3β is a negative regulator in Wnt/β-catenin signaling pathway, 
downregulation of GSK3β result in activation of Wnt/β-catenin signaling 
pathway, and the signal eventually induced a cellular response via gene 
transduction (Ding et al., 2010). 
With the above information, bFGF signaling is linked with telomerase through 
Wnt/β-catenin signaling. We then proposed a possible mechanism of how 
bFGF signaling eventually caused telomerase activity to increase and telomere 
in hESCs: according to previous investigations, bFGF signaling was 
transduced through PI3K/Akt pathway. The signal finally reached nucleus and 
induce the expression of pluripotency genes, which is the main purpose of 
bFGF in hESC culture; at the mean time, Akt also inhibits GSK3β in Wnt/β-
catenin signaling pathway, provide a similar effect as activation of Wnt/β-
catenin pathway. This finally enhances the effect of β-catenin in nucleus 
which includes: (i) expression of pluripotency genes; (ii) expression of hTERT. 
The upregulation of hTERT will then cause increasing of telomerase activity 







Figure 5.1a A proposed FGF and Wnt signaling crosstalking and its effect on 
hTERT expression in hESCs.  According to previous investigations, bFGF 
signaling was transduced through PI3K/Akt pathway and reached nucleus to 
serve its main purpose - induce the expression of pluripotency genes; at the 
same time, Akt also inhibit GSK3β in Wnt/β-catenin signaling pathway, cause 
similar effect like activation of Wnt/β-catenin pathway. The signal releasing 
more β-catenin and finally enhance the effect of β-catenin in nucleus which 
includes: 1. expression of pluripotency genes; 2. expression of hTERT. The 
upregulate of hTERT will then cause increased telomerase activity and finally, 
elongation of telomere. In later experiment, Wnt3a and DKK1 were used to 
activate or inhibit Wnt/β-catenin signaling pathway. Wnt3a activates Wnt/β-
catenin signaling by direct bind to Frizzled family in conjunction with a LRP; 
while DKK1 antagonize Wnt/β-catenin signaling by direct high-affinity 
binding to Wnt co-receptor LRP. 
 
To prove the hypothesis, we firstly demonstrated bFGF signaling could indeed 
modulate Wnt/β-catenin signaling pathway in hESCs. Western blot detection 
of ratio of active/total β-catenin was used here for the measurement of 
activation level of Wnt/β-catenin signaling pathway as previously reported 






Wnt3a and DKK1 were used to activate and inhibit Wnt/β-catenin signaling. 
Wnt3a is known to activate Wnt/β-catenin signaling by directly bind to 
Frizzled family in conjunction with Wnt co-receptor LRP to initiate the signal; 
while DKK1 antagonize Wnt/β-catenin signaling by direct high-affinity 
binding to LRP (Figure5.1a). Our results showed that activation and inhibition 
of Wnt/β-catenin using Wnt3a and DKK1 significantly increased and 
decreased the active/total β-catenin ratio in hESCs compared to non-treated 
control as expected. Most importantly, in this study we also found that there 
was significant increase of Wnt/β-catenin signaling in hESCs treated with 
bFGF for 24 hours (Section 4.3.1). 
In our hypothesis, the inhibition of GSK3β by FGF signaling occurs at 
downstream of the inhibition of Wnt/β-catenin pathway by DKK1 (Figure 
5.1a). To further confirm that FGF signaling upregulate Wnt/β-catenin at 
downstream of DKK1 inhibition, H1 hESCs were treated bFGF and DKK1 
together. Compared to DKK1 treatment alone, the addition of bFGF 
significantly reverse the effect of DKK1, indicated that FGF signaling could 
still activate Wnt/β-catenin pathway even with the inhibition at upstream by 
DKK1 (Section 4.3.1).  
Briefly, we proved that FGF signaling could indeed upregulate Wnt/β-catenin 
pathway, and this occurred at downstream of DKK1 inhibition. 
To further confirm the link from FGF signaling pathway to TERT expression 
in our hypothesis, similar experiments were conducted and TERT expression 
and telomerase activity were analyzed, similar results were found (Section 






DKK1 could increase or decrease the hTERT expression and telomerase 
activity; 2. bFGF treatment significant increased the hTERT expression and 
telomerase activity; 3. bFGF treatment significantly counteract the inhibition 
of Wnt/β-catenin by DKK1. 
To summarize, all above results supported our hypothesis of that bFGF 
increase TERT expression and telomerase activity through crosstalk with Wnt 
signaling. 
5.4 The telomere length advantage can be inherited by progeny cells. 
In this study, we found that telomere length of hESCs is not maintained in a 
rigid range; instead, the telomere length could change significantly according 
in different culture systems or by stimulations (e.g. bFGF). This was not 
reported before in hESCs researches. Although the differences in telomere 
length did not affect the pluripotency of hESC itself, we speculate that a 
longer telomere to start with might give the differentiated cells a privilege at 
least in telomere length.  
In this study, we investigated if the difference of telomere length in hESCs can 
be inherited by the differentiated cells. Two populations of H1 ESCs which 
are genetically identical but with different telomere length (~13kb vs. ~8.5kb) 
were differentiated into ebFs at the same time using same protocol. 
Differentiated cells were both maintained in same culture media and passaged 
at same passage ratio, telomere length was monitored in every 3 to 4 passages. 
Just as previous data showed, telomere length started to shorten immediate 
after the start of differentiation; however, both populations showed similar rate 






advantage over the other population in spite of continuous shortening of its 
own telomere. After 10 passages of culture, the ebFs in long telomere 
population still had telomere of ~9.5kb which is even longer than the H1 
hESC in short telomere population (Section 4.4).  
If we use critical short telomere length of 5kb which we found in this study as 
an end point, the ebFs in long telomere population could possibly be cultured 
in vitro for 10 more passages than those from short telomere population before 
reach cellular senescence. In regenerative medicine, 10 passages can mean a 
large number of cells when preparing for cell transplantation or it can mean 
much longer survival time in patient after transplantation. 
In addition, another study found when hESC was differeneiated into MSC-like 
cells, hESCs with longer telomere showed higher differentiation frequency 
compared to hESCs with short telomere length (Forsyth & McWhir, 2008). 
In summary, we have shown in this study that hESCs with longer telomere 
could produce progenies with longer telomere, compared to its short telomere 
counterpart. And a longer telomere in starting hESCs might provide longer life 
in in vitro expansion and other privileges to its progeny cells. These 
advantages might provide convenience and more potential in later application. 
5.5 Summary of study 
Generally, the first part of this study investigates the dynamics of telomerase 
activity and telomere in hESCs’ differentiation into different cell types. This 
information especially the telomere length dynamic in differentiation and 






regenerative medicine, e.g. when is the most optimal timing to implant the 
cells to patients so that the cells will give the best performance afterwards. 
In the second part of the study, we found there was significant difference in 
telomere length of hESC in different culture systems: hESCs cultured in 
mTeSR™1 system have much longer telomere compared to those cultured in 
MEF system. By comparing the components of the two culture systems and 
conducting related analytical experiments, bFGF was found to play a role in 
regulating hTERT expression and eventually influence the telomerase activity 
and telomere length. 
In the third part of the study, we investigate the mechanism of how bFGF 
cause the change of telomere length in hESCs. We found that FGF signaling 
pathway could upregulate Wnt/β-catenin signaling pathway and eventually 
cause upregulation of hTERT expression which lead to telomere elongation. 
In the last part of study, we demonstrated that hESC with longer telomere can 
pass this feature to its progeny cells and the longer telomere can possibly 
provide the progeny cells with longer in vitro and possible in vivo expansion 
life. 
In conclusion, we have shown in this study that: hESC derived cells are 
susceptible to limited self-renewal and cellular senescence due to the loss of 
telomerase activity. The susceptibility of the hESC derived cells to telomere 
shortening and related cellular ageing might be depended on the telomere 
length of starting hESCs. Finally, we found that telomere length of hESCs can 
be elongated through extra bFGF stimulation and this possibly worked through 






5.6 Questions remained and future studies 
5.6.1 Whether telomere length affects in vivo performance waits to be 
explored 
So far, in this study, all data obtained from hESCs and its derived cells were 
all from in vitro platform. How hESC derived cells shorten their telomere or 
when and how their ageing progress in in vivo environment is far from known. 
Since the ultimate destination of hESC derived cells is clinical application, the 
findings or theories obtained in vitro still need to be verified in vivo. 
5.6.2 Will telomere length affect the efficiency in differentiation? 
To differentiate hESCs to other somatic cells or adult stem cells are the first 
step for its applications in regenerative medicine, the quality of hESCs derived 
cells and efficiency of how they are derived are equally important. No doubt 
that longer telomere would possibly help the telomerase-negative hESC 
derived cells better cope with replicative telomere erosion, but will longer 
cause a difference in the efficiency of differentiation itself still remain to be 
verified. To understand this, more comprehensive comparison studies between 
hESCs with different telomere length are needed in the future. 
5.6.3 What decide the telomere length of hESC remained unclear 
Long telomere and high telomerase activity are two of the key features of 
hESCs; however, high telomerase activity does not elongate telomere 
indefinitely, which means there is a hidden mechanism to keep the balance 
between replicative erosion and telomerase-driving elongation. In our study, 






also indicated bFGF and its downstream or crosstalking signaling pathways 
could also play a part in this telomere homeostasis in hESCs. A thorough 
understanding the mechanism of how and why hESCs maintain their telomere 
length might help us to explore more about the functions of telomere in hESCs 
and equipped us with more tools to prepare hESCs that are more superior in 
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